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Turning Stealth Liposom~s· into ·. Cationic .Liposomes for
Anticancer Drug Delivery

Abstract

by Vijay Gyanani
University of the Pacific
2013
Targeting the anticancer agents sele~ively to cancer cells is desirable to improve the
efficacy and to reduce the side effects ofanticancer therapy. Previous·Jy reported passive

tumor targeting by PEGylated lip()s()mes (stealth liposomes) llaye resulted in their higher
tumor accumulation. However their interaction with cancer cells has been minimal due to
the steric hindrance of the PEG coating.

This dis~rtatiort reports two approa¢hes to enhance the interaction of stealth liposomes
with cancer cells. Firs~ we designed a lipid-hydrazone-PEG conjugate that removes .the
PEG coating at acidic pH as in the tumor interstitium. However~ such a conjugate was
highly unstable on shelf.
Second we developed lipids with imidazole headgroups. Such lipids.· can protonate to
provide positive charges on liposome surface at lowered pH. Additionally. negatively
charged PEGylated phospholipids can cluster with the protol}ated imidazole lipids to

display excess, positive charges on the surface of the liposomes, thus enhancing their
interiction

with

negatively

charged

cancer

cells.
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We prepared convertible liposome formulations I, U and III consisting of one ofthe three

imidazole-based lipids DHI~ DHMI.and DHDMI with estimated pKa values of5.53, 6.2

and 6.75, respectively. Zeta potential measurement confirmed the increase of positive
surface.charge of such liposomes at lowered pHs. DSC studies showed that at pH 6.0
fonnulation r formed two lipid phases, whereas the control Jiposome IV remained a onephase system at pHs 7A and 6.0. The interaction of such convertible liposomes with
negatively charged model liposomes mimicking biomembranes at lowered pH was
substantiated by 3-4- times increase in average sizes of the mixture of the convertible

liposomes and the modelliposomes at pH 6.0 compared to pH 7.4.
The doxorubicin-loaded convertible liposomes show increased cytotoxicity in Bl6Fl0

(murine melanoma) and Hela cells at pH 6.0 as compared to pH 1A. Liposome III shows
the highest cell kill at pH 6;0 for both the cells. The control formulation IV showed no

difference in cytotoxicity at pH 7.4 and 6~0. Uptake of convertible liposome U by
BJ6FIO cells increased by 57% as the pH was lowered from 7.4 to6.0.
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Chapter 1: Introduction

an~er Epidemiology

ancer is a group of dise~ses cbarac~erized by tincontmlled growth ofabnonnal cells that

ave

a potential

to invade other tissues (1,2}. Cancer is a foremost cause of death

·orldwide which lead .t o 7.6 million deaths worldwide (around l3 %of all deaths) i.n
008 (3). The t{)tal number ofc.feaths due to cancer will continue to rise to an estimated
~. J

million in 2030 (3). Iri United States cancer is the most common cal.lse of death

.Jcceeded by only heart ,disease~ American cancer society estimates that in 2013- ab<)ot
80~350

Americans are expected to die of cancer, which acco.uf1ts for 1600 deaths a day

nd nearly one of every 4. deaths. About 1.660,290 new c:ancer cases are. expected t9 be·
iagnosed in 2013 (1}. From 1991 to 2006,. the death rate from heart diseases (most
ommon causeofdeath) declined. to two :thirds but that from cancer declined .much more

Jowly to 83% despite technological advances in medical and allied health fields (4).
!his highlights the importance of anticancer Tesearch and warrants the time,. money and.

1m~rt to~iscovcr novel ways to trea,t cancer.
~ancer Nomenclature and Pathology

rhe term ~cancer· is a derived from the Greek word •J<:arkinos' meaning crab (5). Early
1bseryers s~w spread and persistence ofcancer as crab-like and hence the term (6}. An

~nonnal growth ofcells forming a lesion or lump is called a 'Neoplasm' or 'Tu~ot'. A
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widety accepted definition of Neoplasm by Sir Rupert Wittis (Willis, 1952) states ••an
.!bnonnal mass of tissue~ the growth of which .exceeds· and is uncoordinated with that. of
normaltissue and persists in the same excessive manner after cessation of stimulus which
evoked the change". Neoplasm is characterized by its irreversible nature. Tumors can be
cancerous or non cancerous. Non cancerous tumors, also called benign tumors, are
limited to certain part of body and are not ominous to the host~ White cancerous tumors
or malignant tumors de-differentiate from the tissue of origin and invade to other parts of
the body causing significant damage to the host owing to its uncontrolled growth and
spread.

The development of malignant tumor is a multistep process .comprising of

initiation, promotion and propagation stages.

Initiation of tumor invorves genetic

,alteration in a single cell leading to abnormal growth (8). During the cell promotion
stage actively proliferating cell population is generated by the division of the mutated
cell.

Tumor progression continues as the further mutations of the proliferative cell

population takes place and some of these mutations result in a clone of cells with higher
growth potential. This clone of cells outnumbers other cells in the tumor in a process
called 'clonal selection'. The clone. of cells may undergo fr¢quent genetic alterations to

produce a new clone of cells with higher mutation potential as a result of their ·increasing
genetic instability. The progression stage is thus a multi step process in that a series of
· clone of cells with ever increased proliferative capacity and metastatic potential are
produced (8).
, It is very important for a pathologist to identify the tumor and classify a tumor as benign
or malignant. The criteria for the diagnosis of a malignant tumor· include size of primruy
tumor, the depth of tissue invasion at primaty tumor site, the extent of spread to local
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rmph nodes and presence or absence of distant metastasis (7).

The deliverance of

nticancer therapy depends on the: diagnosis of a malignant tumor.
:'umor nomenclature describes tumor by the tissue of their origin- epithelial. connective~
nuscular or nervous (5). As a general rule; a suffix
ypes whether benign

~oma•

is applied to n¢arly all tumor

or malignant and irrespective ofthe histological origin (5) except

br tumors of hematopoietic and lymphopoietic systems where a suffix •emia~ is used.
Challenges and

Limitations~ of Current Anticancer

Therapies

Current most commonly employed anticancer strategies include sutgery, radiotherapy
and chemotherapy. Although these anticancer strategies have their own advantages-, there
are certain limitations associated with them.
1.1 Ca,neer surgery. Surgery, for instance, may seem to be a convenient option for·
removing solid twnors; but it should be noted that not all tumors can be :surgically
removed. If the tumor is sufficiently big so as to impose serious damage on the
surrounding normal tissue or regular functioning of the organ e.g. nonnal functioning of
brain including thinking, speaking etc. surgery is not considered as an antitumor strategy.
Prostrate, ovarian and uterine surgery may cause pennanent damage to fertility, while
1ung cancer surgery.may cause breathing problems and bre~thlessness. Lung. surgery, in
some instances, has also been known to affect voice and vocal cord tissues. Oral cancer
surgecy· pr<Jcedures ·such· as· Glassactomy although ·may not eliminate the.ability to speak
but speech is not as dear and swallowing may be difficult.

laryngectomy completeTy eliminates regular speaking.

On the other hand

Regardless of the above
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nentioned complications associated with tumor removal
.·
·
· a t vanous
sttes.
surgery itself

Jas inherent issues. such as infection and local nerve damage.
L2· Chemotherapy.

For treatments su~h as chemotherapy either free drug

('f

mo~t

ikely a combination of drugs is administered in the body. Although chC"mOthcrapy is tm~
of the few treatment options for metastasized cancer the- major dr.t\\bad; of
chemotherapy is its poor selectivity. Since cancer cells originate from normal cells that
grow out ofcontrol~ anticancer drugs that suppress gro\\th of cancer cells also a fleet the
growth of no]lilal cells. The poor selectivity of common chemotherapeutic drugs is due
to the proliferative nature of cancer cells. Not only that the anticancer drugs have toxic
effects on cancer cells, they also have potential to impose serious damage to ~me
marrow. gastrointestinal tract and hair follicle (9). To cite a few cxamplr:s: the dose~
limiting hematotoxicity including thrombocytopenia and neutropenia are prevalent in
carboplatin and/or carboplatin in combination with other chemotherapeutic agcnls. Skin
effects especially keratitis are common side effects of chlor:ambudL Cisp1atin has been

known to accumulate in the kidney by a transport mediated _process aflcr continu(lUS aod
prolonged exposure and caqse severe dose dependent tubular and glomerular dysfunction.
mitochondrial swelling and nuclear paUor in distal nepltron (11 ). Cumulative toxidt~·
due to Anthracyclines, doxorubicin being a most common example~ may cause
cardiomyocyte damage and apoptosis due to production of free radicals and acute
·
· ·· that
· may ·me1ude arrh ythm..tas. penca
• rditis mvocarditis and acute hcan
cardtotoxtclty
,·
*·

failure.

Additionally~

.

chronic cardiotoxkity associated with anthracydines include

··b

.·

conditions such as left ventricular dysfuncuon. For reast can

cer treatment in particular.

"1 (CMF).ree:imen has been known

the cyclophosphamide~ methotrexate and 5-fluorouract .

· · -
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' cause neutropenia, alopecia and emesis (14). In case of 5-fluorouraciJ .containing
:gimens e.g. cyclopho$phamide, doxorubicin (Adriamycin), and 5-fluorouracil (CAF) or
·fluorouracil, doxorubicin, and cyclophosphamide (FAC), mucositis appears to be

ommon than non fluorouracil regimens like doxorubicin and cyclophosphamide (AC)
14). It is interesting to note that paclitaxel when administered in higher dose (i.e. 225
.1glm2) in sequential regimen has shown severe .and recurrent neuromuscular toxic"ity as
ompared .to lower dose (i.e., 175 mg/m 2).
Jesides aforementioned notable examples of severe .side effects of chemotherapeutic

1gents, there are cases where patients are beleaguered with side effe-cts that are not
nalignant but do have a significant effect oil the quality of life and may result in
:liscontinuation or undue disruption of chemotherapy. Skin diseases are the prominent
l1110ngst them (16).

Common side effects on skin i.e. skin rash, skin dryness.

hyperpigmentation and on mucosal membrane include Steven Johnson Syndrome and
toxic epidennic necrolysis are cau-sed by commonly used drugS such as
Cyclophosphamide, Chlorambucil, Busulfan and Procarbazine. Novel anticancer agents
such as EGFR inhibitors markedly cause skin dryness and follicular rash which can then
result in pruritis or other infections (16). The most common ofthe follicular rash is the
papulo-pustular rash. Other common skin e.ffects such as Erythma and sweUing are
associated with administration of antimetabolites such as 5~Fiuorouraci1 and capecitabine
(16).

In .addition to the poor· selectivity of chemotherapy mentioned hitherto, the other major
limitation is the development of rnultidrug resistance (MDR) (Fig. 1.1). Cancer cells
may develop resistance that might begin against a single drug or a group of drugs with
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similar mechanism of action but may transfonn into cross resistance against other drugs
with different> targets or mechanism of actions in a process called. multidrug. resistance
(MDR) (27).

MDR leads to growth of ·heterogeneous cancer cells due to mutator

phenotype as a result of selection of cells that are ·able to gr.ow in the presence of
chemotherapeutic drug/s (27). Drug resistance in cancer cells is developed either by

modification in drug target or by enhancement ofthe repair mechanisms of the cells such
as DNA repair and induction of cytochrome oxidases(27), Additionally, one of the most
prominent mechanisms ofmulti..drug resistance is the over-expression of ABC binding

cassette transporters based efflux transporters. The increased effiux transporters· reduce
the amount of drug to suboptimal 1eveJs in the cells (27). MDR can also develop from
reduced intracellular uptake of hydrophilic drugs e.g folate analogues• .cisplatin etc. (89).
Examples for the later are ciaplatin, methotrexate, 5 fluorouracil etc.

Funhennore

inefficiency in apoptotic · cycles ll}ay .lead to ·MDR, precisc~ly due to ineffective p53 or
alterations in ceramide levels.
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Fig. 1.1 Overexpression of Pgp transporter proteins leading to efflux of drug from the
cells. (Reproduced from (92))

Of the reasons mentioned above and the fact that chemotherapeutic agents have narrow
therapeutic index in that there is a small difference in the dose required for an anticancer
effect and the dose causing significant toxicity, limits the therapeutic implication of
chemotherapy. Furthermore, the damage to normal cells entails reduction in the dose of
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he anticancer drug which eventuany leads to inefficient disease control~ drug resistance
md metastasis.

1.3 RadiQfherapy.
~mploys

Radiotherapy, another commonly practiced anticancer therapy.

the use of high energy X rays for the treatment of cancer. The applications of

radiotherapy vary from tumor kill to tumor shrinkage to pain. relief.

While the side

effects of an anticancer drug or a combination of drugs are systemic. the .side efTt-cts of
radiation therapy are more of the local nature (in the proximity of the tumor). Radiation
side effects on patients are manifested either·as early effects or late ·effects. Early effects
are mainly skin related effect.~ which include skin erythema and desquamation. Late

radiation effects include

fibrosis~ atrophy, radiation

induced blood vessel and ncuronar

damage. While it is important to note that short term effect-are reversible, late effects are
either irreversible or aggravate with time. The response manifested as late effects are

. medi;:tted by inflammatory; stromal, endothelial and parerK:hymal cells. Fibrosis. one of
the late effects. is characterized by excessive extrncellular matrix and collagen deposition
in region of irradiated tissues. The early phase offibrogenesis is simi-lar to the·wound
healing process characterized by initiation of cytokine·cascades essentially marked by
release oftumour-necrosis factor-a (TNFa),Jnterleukins I and 6 (IL 1 and IL6} and other
growth factor in the irradiated tissue ( 17). While in a regular wound healing process

TNFa and connective tissue growth factor (CTGF) downregulate· TNF f3 which is a strong
fibrotic factor; the wound healing in irradiated tissues continue for years7 which leads to
fibrosis of tissues (J 7). Al)other aspect. of radiation side effects is the kno""n to be
affected by the reduced oxygen content (hypoxia) in the tumor environment. lt is
reported that radiosensitivity of cells is diminished due to hypoxic environment which
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nduces high J¢vels .o f heat shock pt6t~iit in tumor cetlsand also stimulate io.creasein
.tu.mber of cells with high proliferative capabilities (13). Specifically the increased
txpression and stabilization of hypoxia inducing factor· HIF 1 a is responsible for the

jncrea$e in

radiotesi~~ce

Qf cells~ The HIFt a expression is increased by activation of

phosphatidylinositol 3-kinase (Pl3K)/Akt/mamma1ian target of rapamycin (mTOR)
pathway and increased stability of HIP I a by itS interaction.with Heat shock protein 90
(Hsp 90) (18).

Tumor Targeting and its Challenges
As mentioned earlier chemotherapy .and radiotherapy have many side effects and the
most common reason for chemotherapeutic.side effects is the .non specific, .indiscriminate
effect on nonnal and tumor cells.

The anticancer dtug effect has its basis in fast

multiplying cancer cell lines, which therefore can affect rapidly dividing nonnal ceJls. It
is interesting to note that only 5-10% of the drug administered reaches. tumor tissue (25).
Paul Ehrlich introduced the tenn •magic bullets 1 to selectively target a drug.to disease•
~ausing

organisms. Since then a number of targeted drug delivery systems have been

, develo~. Most of Qle nov¢ld¢g delivery systems developed in the past few decades
include liposomes, prodrugs, polymer cpnjugates, micelles and dendritic systems. tumor
.targeting approaches. can be broadly divided .into two categories: Active' and passive
targeting.

1.4 Active .targeting.

Active targeting exploits phenotypict biochemical and

morphological differences between nonnal and cancer .cells (26). Most common tumor
targeting strategy employ biologically specific interactions .such as antigen-antibody or
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ligand·receptor binding for delivering cytotoxic agents locally in the tumor tissue and
may .involve drug uptake by receptor mediated endocytosis through association of the
drug or drug carrier molecule with the antigen or ligand (26). Precisely~ tumor targeting
incorporates tumor specific ligands on nanocaniers/drug conjugates that can bind and
deliver antiCancer drugs to tumor cells, thereby sparing normal cells. Conversely, antigen

heterogeneity in cancer cells presents a major limitation to activ.e targeting; .different
types of cancer or even same type of cancer.at different .developmental stages express
different pathological and biochemical profiles. Receptor density is also an important
parameter in active targeting. It is crucial that the number of receptors/targets is overexpressed in the tumor cells compared to nonnal cells. For example~ a receptor density

of I 0~ per cell (29) of ErbB2 is required for improved breast cancer therapeutic efficacy.
Similarly Bcell targeting by liposomes grafted with anti-CD 19 antibody requires a.-CD 19
density in the range of l 04 - 1os per cell (28). Atany stage of cancer development downregulation or shedding of antigen from cancer cell surface might severely affect
therapeutic outcome. Shed antigens circulating around cancer cells may compete- for
binding of the ligand and therefore reduce the binding and internalization of the
therapeutic agent(29). Furthennore, if the binding.affinity between the targeting ligand
and its teceptor is too high it wi11 hinder the quantitative uptake of anticancer agent in the
tumor due to high affinity binding with the first few target cells - a phenomenon known
as binding-site barrier (29).

As an example, Adams et al (30) showed that bio-

distribution of single chain Fv molecuJ~s {SCFv) in SK·OV-3 tumors is regulated by the
binding affinity of the SCFv molecules to the her2neu receptor overexpressed by the
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:sneer cells.

The excessively high binding affinity of mutant scFv beyond l 0-9 M

~tateaued the quantity ofscFv distributed
/.4~1

in the tumor (30).

Antibody. and ,Qntibody fragments.

As targeting agents, whole antibodies are

stable in solution but are usually immunogenic and can bind to macrophages via the Fe
domain, thus increasing their clearance and shortening their circulation half Jives (29).
To reduce the immunogenicity of antibodies, chimeric or humanized antibodies were

developed but their· production is very expensive. Addtionally, large antibodies when
used as targeting moieties for ilan()particles thwart attempts of multivalent decoration on
the rtanoparticJe. surface due to the steric hindrance. Antibody fragments. on the other
hand. sucfl. aS.the .Fab or scFv <fontains are mote Spt!cific to their targets but have stability
issues Md carry less avidity due to their monovarent binding domain.
antibody small molecules such

When

non~

as RGD, folate and transferrin are used as the homing

moiety, the targeting is not exclusive to tumo.- tissues and affect nonnal tissues. Also.
free folate molecules present in the body .can compete with the forate target ligand for its
receptor on cancer cell surface (29).
].4.2 Immunotoxins and ·immunoc(}njuglllts. lm.rnunotoxins and lmmunoconjugates.

although have been recently clinically approved but find limitations for anticancer
therapies due to their moderate to severe side effects. Immunotoxins are either antibodies
or antibOdy derived proteins that are linked to. toxins. Patients

on immunotoxins as

anticancer agents have expressed high levels of hepatic transaminase levels; indicating
localiZation of toxin in liver; Additionally flu·like symptoms and vascular leak syndrome
have been observed in patients

on

immunotoxins.

Anti B4 blocked ricin have

demonstrated Human antimouse antibody responses and anti~ticin responses (29).
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mmunconJugates are similar to immunotoxins except for the c)1oto~ic drug :is linked to
fie antibody or protein instead of the toxin. Jmmunoconjugates-works on the principal of

mtigen-antibody binding as mentioned earlier. The major limitation these systems is the
aumber of drugs linked to antibody. On an average 3-lO molecules of drug have bc.cn
known to be attached to an antibody molecule without affecting the antibody binding
affinity (29), e.g. approximately 8 molecules of doxorubicin are coupled w'ith AR96
antibody (31). lmmunoconjugates have shown limited success due to: l) large number
of antibodies needed to .deliver therapeutic amount of drug 2) reduced

intemali;~.ation

of

drugs 3) suboptimal drug release from the conjugate (29) 4) toxicities induced hy the
treatment~ e.g.

severe gastrointestinal toxicities induced by BR96-Dox.. immunoconjugate

(Jl).

1.4.3 lmmunoliposomes. Liposomesare nanometer lipid bilayer vesicles with aqueous
interiors that can encapsulate hundreds of thousands ()f drug mol~:culcs and thus address

the issue of limited number ofdrug molecules bound to the antibody or any other ligand.
thereby reducing the high amount ofimmunoconjugates required to be administered

tO

have sufficient drug at the tumor site. ImmunoJiposomes, are Hposomes with targeting
antibodies attached to their surface. The high payload ensures very high drug to antibod)·
ratio.

However, the challenges with immunoliposomes are similar to .other acti\'e

targeting approaches viz .. the decoration of 1arge number of antibody molecutcs on

liposome surface increases their clearance~ development and production.

The

receptor/antigen density and the avidity of ligand for the receptor/antigen may pose
·
1·u.at10n
· · ·tssues or
· the ·b··md.•mg-stte
• bamer
· phe·no·men·on
leading to limited tumor
mterna
.
penetration and reduced cytotoxic effect on antigen negative cancer cells.
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1.5 Passive tumor targeting. Passi"·e targeting of nanocarriers does not employ any
targeting ligand but relies only on the 'Enhanced Permeation and Retention' eflect (Fig.
1.2) for their accumulation in the tumor tissue and retention in the tumor cells. The
enhanced penneation of nanocarriers in the tumor occurs due to leaky tumor vasculature
while the retention of the nanocarrier at the tumor site is due to the dysfunctional
lymphatic drainage (28).

Although the challenges imposed by active targeting e.g.

antigen heterogeneity, ligand avidity etc are not associated with passive targeting, it has
certain limitations. The major limitations associated with only liposomal systems will be
discussed here.

No~··.··.·· ··.

Fig. I .2 'Enhanced Permeation and Retention' effect showing the extravasation of
liposomes in tumor tissue (reproduced from http://www.regulon.orglprofile.html)

1.5.1 Conventional /iposomes.

The first generation liposomal introduced were the

conventional liposomes (90). Upon intravenous administration conventional liposomes
are recognized and captured by the reticuloendothelial system (RES). This approach has
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been exploited in treating. parasitic and microbial infections of the RES.

A classiC

example is Ambisome (ArnB) which delivers amphotericin B. to fungus-infected

macrophages.

However~

conventional !iposomes have miniiJ1al effect beyond cells of

RES due to extensive blood clearance and short circulation half life·(JS, 36), Semple et

al

(40)

reported

that

cationic

Uposomes

made

of

l~.-dioleyl-3-N,N,N

trimethylaminopropane chloride (DOTMA):DOPC (1 :1 mol mor 1) and DOTMA:DOPE
{1: 1 mol mof 1) have a protein bitlding (PB) value in excess of500g protein /mol and are
cleared rapidly from circulation in mice (40). Inclusion of 50% of the cationic lipid
DOTMA in the liposome composition results in strcmginteractions with serum protein to

the extentthat they together form. Clots in plasma ( 4 t). A similar formuJation employing
DODAC instead of OOTMA with DOPE acquired a PB value of 800 g protein /mol and
had a circulation half life of only few minutes ( 40). A series of cationicliposomes made

by oku et al, 1996 (42) have displayed PB values ranging from 400--11 O() g proteins/mol
of total lipid (40), (42). The results are not surprising considering the fact that majority
ofplasmaproteins carry negative charges at physiological pH (40).

Different approaches have been employed to increase the circulation half life of

Uposomesin vivo~ Papahadjopoulos. and coworkers (39) prepared stericaUy stabilized
liposomes with hydrogenated phosphotidyl inositol/ phosphatidyl choline/ cholesteror
(HPIIHPC/chol) which showed a liposome.. assodated doxorubicin half Hfe .of 15.5 hrs

while conventional fiposomes based on egg-derived phosphatidyl glycerol, phosphatidyl
choline and cholesterol showed a liposome associated drug half life ofonly l hr·
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·1.5.2 Stealth Liposomes.. Another strategy to im_prov(lip()sc>rne blood circulation time
is to coat a hydrophilic polymer such as Polyethylene Glycol (PEG) on the Jiposome
surface.

The mail\ fe~ture of having PE:O gra6ed on the liposome surface is the

flexibility· which permits a SJ11all percentage of PEG~lipids on the liposome to imp;1rt a:
stericalJy stabilized hydrophilic shell around the' Hposome. The hydrophilic, sterically

· stabilized PEG coating reduces adsorption of serum proteins

on Uposomes

and their

subsequent Clearance by the R.ES. As the PEG ~ides the surface of liposotne from being
recognized these liposomes are called 'stealth liposomes'. The drug epirubidn has a

halftife ofonly 14 min. However, when encapsulated in Stealthliposomes (SL)the half

life increased dramatically to 1S hrs. Also, the free epirubicin and its SL encapsulated*
epirubicin showed more than 200-fold difference in both AUC and in clearan~e (39).

An example of stealth

liposome~

which is now commerciaJly available is 'Ooxil'·

. manufactured by Janssen Phannaceuticals (Fig. 1.3).
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Doxorubici

Hydrogenated
Cholesterol

PEG

Pig. J.3 Doxil coated with Polyethylene Glycol (adapted from {94)

The protein binding values of PEGylated liposomes are reported to be much lower
compared to the conventionalliposomes. Semple et al (40) reported that liposomes made
ofDSPC:CH and EPC:CH:DOPA in a lipid mol ratio 55:45 and 35:45:20 had PB values
of 19 and 46 respectively. When 5% DSPE-PEG were included in above compositions
the PB values dropped to 7 and 25 respectively ( 40). Du et al ( 46) showed that adhesion
of erythrocytes, lymphocytes and macrophages onto glass surface coated with
DPPE!DSPE-PEG liposomes drastically decreased as the DSPE-PEG mol% in such
liposomes increased from 0 to 1%. However, the rate of decrease slows d0\\11 ac; the PEG
mol% increases further from I to 5 %.
Despite the increase in the accumulation of sterically stabilized Jiposomes in the tumor
vicinity, the steric hindrance of the polymer chains on the liposome surface has posed a
challenge in the interaction of liposome with tumor cells. Hong et al 1999~ (43) reported
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that the Te (AUCtumor/AUCplasma) ratio of DSPC/CholesteroJ liposomes were 0.87
compared to0.31 in the PEGylated liposome with 6% DSPE-PEG in mice bearing C26

tumor. Similar findings were reported by ·Parr et al 1997; (44). where DSPC/Cholesterol

and DSPC/CholesteroJIPEG-PE liposomes in Lewis Jung model suggesteda Te vaJue of
0.76and 0.4 respectively.
The reducedinteraction and bmdin~ ofstericaUy stabilized Jiposomes with· tumor ceUs
reduces intracellular uptake .of these caniers which causes the therapy to completely rely

on the slow release of encapsulated drug from the liposome which might be ·suboptimal
for tumor elimination.

Strategies of Triggered Release from Liposomes.
To increase the release of drug from the liposornes various strategies have been

introduced including external stimuli (ultrasound; light and temperature change) but each
one of them. have their-own challenges.

1.6 Triggered release by ultrasound. Ultrasound is a non invasive technique which
can be focused to target tissues~ can- alter the penneabiJity ofcell membranes and can be

controlled (47) (48). Acoustically active liposomes (ACL)~ Hposomes that have air
pockets and are responsive to reduced pressure or ultrasound, prepared by Huang et al
(47) used

ultrasound as the triggering mechanism for calcein release from

EggPC/DPPEIOPPG/CH liposomes at a molar ratio of 69:8:8:15. Although the calcien
release was carefidly controltedt the encapsulation efficiency of calcein during lip<>some
preparation was

very

low (~ 20%) and the encapsulation and triggered release of

hydrophobic. drugs remained untested.
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: 1.7 Triggered

release

ligllt.

by

The

ligbt·sensitive

Jiposomes

exploit

photoisomerzation, photocleavage or photopolymerization of photoresponsive lipids in
liposome membrane.

The majority of photoisomerizable liposomes incorporate.

azobenzene lipids that isomerizes to cis fonn upon -illuminated by ultraviolet light and
switches back to the trans- fonn upon exposure to blue light (49) (Fig. 1.4 (a)).
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Fig. 1.4 (a) Drug release from liposomes by photoisomerization of lipids
(Reproduced with permission from (49))

Conversion to the cis- fonn can destabilize the membrane and release drug contents.
Although azobenzene derivatives have been extensively studied, retinoyl-phosphoJipids
(50) and spiropyran, which converts to merocyanine at low wavelength of 365 nm have
also been reported (51).

The major drawback of photo-isomerization is that the
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wavelength required

to

photo-isomerize the photosensitive lipids is in the lower range

(lower visible or UV) which has limited penetration in the body.
The second major strategy of triggering liposomes by light is to incorporate
photocleavable lipids in the liposomaJ membrane (Fig. 1.4 (b)). Thompson et al (52)
reported the use of photocleavable lipids derived from plasmologen. Photocleavage is
enhanced

by incorporating photosensitizers

such as zinc

phthalocyaninet

tin

octabutoxyphthaJocyanine, or bacteriochlorophyll a. into the hydrophobic region of the
Jiposomal bilayer (42).

b

Fig. 1.4 (b) Drug release from liposomes by photocleavage of lipids
(Reproduced with permission from (49))
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Apan from naturally occurring plasmalogen lipids, synthetic photocJeavabte dithianebased lipids have been reported (53) (54) to increase the drug release from liposorttes.
Interestingfy Zhang and coworkers synthesized a DOPE-based photocleavable lipid
called NVOC-DOPE which upon· illumination by xenon lamp yielded free DOPE and

subsequent membrane destabilization.
To date, the .most successful of

an the

photo-induced triggering mechanisms is the

plasmalogen based photosensitive liposomes although the sensitization ofphotocleavage

of -plasmalogen by sensitizers have resulted in production of reactive oxygen species
which compromises the ,safety in patients.

A third light-induced drug releasing mechanism is the· photo•polymerization (Fig. lA
(c)).

The polymerization of cross a linking lipid 1,2-bis(l0-(2\4•-hexadienoyloxy)-

decanoyl}·sn-phosphatidylcholine in Hposomes up<>n UV illumination yielded more than
I 00-fold increase in the release of fluorescent agent (56). The wavelength of the UV
light can be adjusted by encapsulating pbotos~nsi~izer dyes· that can trigger the
polymerization of lipids at higher wavelengths of light that are considered biologically

safe. The incorporation of l, 1'-dioctadecyl-3,3.3',3'• tetramethylindocarbocyanine iodide
(Oil) dye is one such example (49).
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c

Fig. 1.4 (c) Drug release from liposomes bypbotopolymerization of lipids
(Reproduced with pennission from {49))

Although similar to photocleavable triggering strategy in tenns of safe wavelength range.
the stability ofpolymerizable lipids have not been tested yet (49).

In a photochemical triggering approach, O.V. Gerasimov et at, who

explon.~

photo-

oxidative triggering in Bcbl:DPPlsC Hposomes, suggested that the photo-oxidative
triggering method is severely limited by the low P<n level in the tumor environment. The
ineffective photo-oxidation leads to creation of physiologically conducive atmosphere for
growth of non apoptotic cells due to faulty photo-oxidation of tumor tissues (57).

1.8 Triggered release by hyperthermia. Yatvin et al {58) in 1978 reponed heattriggered release of neomycin from thennosenstive liposomes.

An array of

thennosenstive liposomaJ syStems have since then been developed to increase the drug
release at the tumor site. The thermo-triggered release approach is multifaceted in that
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· the application of heat I} enhances vascular penneability and therefore accumulation at
the wmor site, 2) e~ the release of drug from thennosensitive liposome at the
, tumor site, 3) probably increases localized blood supply and alter the intracellular uptake

,: of drugs. Fig. 1.5 aptly illustrates the first two points.

Fig. 1.5 A) enhanced accumulation ofliposomes by EPR 8) increased pore size of tumor
vasculature C) increased drug release from the liposomes. (reproduced with permission
from (59))

Traditionally

tbennosensitive

liposomes

have

employed

lipids

that

undergo

conformational change from the trans- form to the gauche- form. (59) at the lipid
transition temperature, which converts the lipid membrane from the gel phase to the
liquid crystalline phase of higher fluidity, which in tum enhances the drug leakage from

the liposome. However the incorporation of purely lipid of lower melting temperature
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such as DPPC (MP = 41°C) has.shown slow and less amount of drug release. Also. the
retention of drug molecules during circulation has been challenging. Incorporation of
lipids .of higher melting temperature such as DSPC (MP

= 54°C) to increase

packing

incompatibility and therefore enhance drug release yielded broad peaks in Differential
Scanning Calorimetry and n~cessitated higher triggering temperature (higher than 43°C)

which can cause necrosis to nonnal tissues surrounding the tumor tissue. An estimate by
Mosher.er and coworkers (62) showed that the initiation of necrosis on porcine muscle
begins after .30 min. of heat application at 40-43°C. Fine tuning the drug release at mild
hyperthermia conditions (3941°C) while maintaining the sharp melting peak so as to
ensure efficient drug release

in ·1ethal doses remains a challenge for thenno·sensitive

liposome research.
Another approach of .preparing thennosensitive liposomes is the incorporation

of

Jysolipids in the. lipid membrane. Lysolipids are lipids that have bulkier head group with
single acyl chain. These lipids typically fol'IIl micelles at]d the lateral movement of these

lipids as the temperature approaches transition. results in the accumulation of these lipids
at pockets which start melting first, thus creating a micelle like curved structure at these
pockets (Fig. 1.6).
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Lysolipid-\."()Urainjng thermosensitiv«j · uposome

Fig 1.6 Traditional and lysolipid containing liposomes.
(reproduced with permission from (59))

The formation of curved structures releases drug through the pores thus formed.
Needham and coworkers (63) incorporated 10 % of the lysolipid MPPC in liposomes
which resulted in reduction in phase transition temperature from 430C

to 3940 °C and

rapid drug release (approx. 500AJ released in 20s heating at 42°C). In general induction of
lysolipids in liposomes drasticaUy reduces the heating time which in tum reduces the
possibility of onset of necrosis in surrounding tissues (59). However, the in vivo stabi.lity
of the lysolipid containing liposomes remains a cbaUenge. Banno and coworkers (65)
reported that 70 % of the lysolipids were desorped from the liposome surface in vivo
after one hour of injection and the amount of drug released from the Jiposomes recovered
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from mice plasma after and 4 hrs of injection was 20% and 50% less. This suggests
decrease in thermo sensitivity of liposomes after desorption of lysolipids. Sandstrom et
at (66) demonstrated release of 50 % drug from lysolipid liposomes after I hour of

injection in vivo.

The application of heat has been thus fart limited to superficially located tumors with
regional heating. For localized hyperthennia microwave and radiowave applicator have
been used (64} but the therapeutic depth of the external temperature stimuli is limited to 3
em. For deep seated tumors microwave and radiofrequency electrodes with expandable
prongs can be used but this approach remains invasive and is limited to the body area

where insertion is practical (59).
Focused ultrasound although has been developed that can control the temperature

remotely in deeply seated tissues with restricted focal zone but the monitoring of
temperature still is done by invasion of temperature probe (59).

1.9 Triggered release by magnetic field from magnetic liposomes. Another strategy
to triggered drug release is the application of magnetic field. Amstad et aJ. incorporated

lipid coated iron oxide nanoparticles in the liposome membrane (Fig. 1.7) and showed
the enhanced release of contents upon application of alternating magnetic field (AMF)

due to local heating by iron oxide nanoparticles and thereby increase in membrane
penneability. (68).
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Fig J •7 Iron oxide nanoparticJes incorporated in lipid membrane.
(reproduced with permission from (68))

Similar work was done by Babincova et al (69) where increasing concentration of
ferromagnetic material in the membrane showed increased membrane penneability viz.
as much as 70 %release of adriamycin at a ferocolloid concentration of J.2 mg Fe/mL
Another approach to prepare magnetic liposomes is to encapsulate magnetite particles in
the Hposomes which can then be directed to the tumor site by placing a magnet in the
tumor vicinity externally.

Nobuto et al (70), showed that the application of steady

magnetic field of 0.4 tesla around tumor implanted limb of Syrian male hamsters
increased the dox. concentration in tumor by 3 to 4 fold after intravenous administration
of the magnetic liposomes. In the similar limb tumor model design, (71) instead of
externally placing a magnet, magnet or non magnetic alloy was placed in the center of the
tumor.

Intravenously administered, adriamycin-loaded magnetic Uposomes showed
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~ignificant antitumor activity and greater accumulation in tumor vasculature under

,magnetic force compared to magnetic liposomes without magnetic torce (non magnetic
alloy).
ln one example, Hposomes loaded with Tc 99 albumin resulted 25-fold increase in
;radioactivity in the left kidney of the rats under study where SmCo magnet was implanted
compared to the right kidney without the magnet (72).
: In an interesting study (73) RGD coated magenetic liposomes were first uptaken by
•· monocytes and neutrophils and then magnetically directed to brain for the delivery of the
model drug diclofenac sodium.
Furthermore, Magnetoliposomes prepared with bacterial magnetic particles containing
• cis-diamminedicbloroplatinum (II) (CDDP) have been observed (74) to have 1.7 fold
concentration at tumor site than the one ones prepared by artificial magnetic materiaL
Conclusion
Commonly employed anticancer therapies and common tumor targeting strategies were
reviewed and their limitations and challenges were discussed. Although active targeting
employs specific ligand to enhance the drug delivery, antigen heterogeneity, high cost of
production~ immunogenicity and insufficient stability remain as its pressing challenges.

Passive targeting by liposomes is an attractive approach to bypass these issues but the
release of the cargo drug needs to be optimized. Because the drop of pH is involved in
the interstitial space of many solid tumors, it serves as an attractive approach to trigger
the release of anticancer drugs from liposome. Liposomes that respond to low pH (pHsensitive

liposomes)

will

be

discussed

in

the

following

chapters.
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Chapter 2: Add Labile Linkers for the Design of pH-Sensitive Lipids and
Liposomes

The pH gradients in the tumor tissues present an interesting trigger. The pH in the tumor
interstitium is 6.5 to 7.0 while the pH of the tumor core may be as low as 6.0. Once the
fommlation

is endocytosed

it meets

even

lower

pH

environment

in

the

endosomal/lysosomal pathways where the pH is 2~3 units lower than in the blood
circulation. Such lower pH can be exploited for either increased intracellular uptake of
liposomes in the tumor tissue or destabilization of the liposome membrane for drug
release intracellularly.
One attractive approach of designing pH-sensitive liposomes is to incorporate pHw
cleavable lipids in the Jiposomes.

pH-cleavable lipids can be constructe-d by

incorporating an acid labile linker betWeen the hydrophilic head and lipophilic tail of the
lipid. The acidic environment cata:lyzes the hydrolysis of the lipid. An ideal liposomal
formulation made of pH-cleavable lipids will be relatively stable at physiological pH and
will destabilize upon cleavage of pH sensitive lipid either in the tumor environment or in
the endosome/lysosome compartment of the cancer cells to release drug contents. Cordes
and bull (76) have described the mechanism and catillysis of acetals. ketals and
orthoesters. A number of acid-labile lipid structures have been designed to study their
enhanced cytotoxic effects. The hydrolysis mechanism and pH sensitivity of such lipids
are

discussed

m

this

section

according

to

their

acid-labile

linkers.
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Acetal.Linker

Acetal Jinker (Fig. 2.1) is an acid-labile linker where one carbon is attached

to

an alkyl

group; a hydrogen atom and two alkoxy groups~ The acidic hydrolysis oftheacetallinker
is shown in Sebeme 2.1
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R'OH

OR"

OR"

11
H

R"OH

+

RCHO

::::--..0

CI

R-C-H

~)
.. .

H•
Scheme 2.1 Acidic hydrolysis of Acetal

Song and Hollingsworth (77) designed pH-sensitive acetaJ·based glycolipid (Fig. 2.2)
and measured its pH sensitivity in ethanol. While 0.01 %addition of DCJ started acetal
cleavage which completed in 5 hours, addition of acetic acid from I to 20% did not show

any ·significant acetal .cleavage after 14 hours of observation under NMR. The pH
sensitivity ofthe acetal based glycolipid remains to be tested in vivo.
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Fig. 2.2 pH-sensitive acetal based glycolipid

' Asokan et al in 2004 (78) designed a ' his-detergent' BD2 (Fig. l.J) by cross linking two
single chain tertiary amine detergents through an acetal linker. The pKa of headgroup

, was detennined to be 6.37 ± 0.36. Liposomes prepared by 75 mol% of BD2 and 25 mol%
: of phosphatidyl choline demonstrated a hydrolysis half life of 3 brs at pH .5.0 and showed
' complete hydrolysis at pH 4.0 after 6 hrs. The design of 'his-detergent' irreversibly
.

.

, cleaves two single chain lipids which results in disruption of Jiposomes and release of
drug content(Scheme l.l).
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OH'YN............._,OxQ~N~OH
OH
.
OH

Fig. 2.3 Chemical Structure of BD2 lipid

S~heme 2.2.Mechanism ofacidc~y~hydrolysisBD2lipid.
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The Hposomesnutde ofBD2 were shown to enhance the intracellular deliveryofTexas
red-labeled oligonucleotides (TR·ON) and ON-705 compared to liposome with BDl

lipids (bis-detergent without pH labile linker}.

;Vinyl Ether Linker
··Vinyl ether (Fig. 2~4) is another linker which is relatively stable
hydrolyzes in acidic environment (Scheme 2.3).

Fig. 2.4 VinylEther Linkage

ar neutral. pH

and
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Scheme 2.3 Hydrolysis mechanism ofVinylEther under acidic conditions

.

.

Thompson and associates (79) have designed a series of Hpids (Fig. 2.5) with vinyl ether
linkages betWeen the lipid tail and p0iar head group. · They prepared liposomes with
DOPE and pH-sensitive vinyl ether lipids. The mol %ofOOPE was 90 %or higher, the
high percentage of DOPE helps the transition of liposome from lamellar to hexagonal
phase as the head group of vinyl ether pB-sensi.tive lipid cleaves from the lipid. The
conversion of the liposorne from lamellar to the hexagonal phase is dependent upon the
kinetics of acidic hydrolysis of vinyl ether group. The best fonnulation that could
achieve content release as much as 60"/o when calcein was uSed as a model dye was ST
352/DOPE in the molar ratio 5/95 after:::::. 4~ hours at pH 4.5. The slow release of
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~ontents from the lipO.s<>me suggests slow rate of hydfQiysis of pH-sensitive vinyl ether
lipids ai:td therefore slower transition from lamellar to hexagonal phase;

(n=4S)
(n= ll4)
0

0

0

0~o)lN.A.v<>-:"f-01
· MeOfv-00NJ-.o""'v
H
H
· a0

'

II

;
·

0

(n=4S)
(n=l14)

Fig. 25 Vinyl Ether lipids prepared by Thomson and Associates

· Thompson and assoch1tes .(80) in 1998,.synthesized vinyl ether based pH-sensitive lipids
(DPPfsC) (Scheme l.4) where vinyl ether was linked between each of the two

hydrophobic tails and the rest of the lipid

molecule~

Although the liposomcs made of

DPPisC were very stable at pH 7.4 the calcein release kinetics of these liposomes
suggested less pH sensitivity (see Table 2.1).

:so
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w
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-·Qlg'
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'"-A.. .Yl•
tt _ ._·_

HO _, - ~

-P-~

l

.

()"
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Scheme 2.4 Acid catalyzed hydrolysis ofDPPisC

Table. 2.1 pH Dependence of 500/o Release Time of Calcein

pH

~%

release (min)

2.3

1.5

3.2

3.6

4.5

76

5.3

230

6.3

1740

The calcein release studies from liposomes made of pure DPPisC at 37°C indicate that
the time required to release 50% of calcein was::: 4 bat pH 5.3 while it took ::::: 29 h for
50% caleein release at pH 6.3. Slow calcein release at lowered pH coupled with the fact
that .no calcein release was detected after 48 hrs of incubation at .pH 7.4 suggest high
stability of liposomes and less pH sertsitivity ofthe vinyl ether lipids. However, less pH
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sensitivity at lower pH's reduce the release ofencapsu1ated contents from the Hposomes.

,-Another study by bergstrcJ.nd et al, (82) employed. DHCh~MPEG 5000 (Scheme 2.5)
lipids where vinyl ether ~as linked between PEG 5000 and hydrogenate(f cholesterol.
i The

leakage percent ofD}lCh-MPEG 5000!DOPE Hposomes at am.olar ratio of 1:99 was

about 22 % after 20 hrs ofincubation at pH 4.5. Also, even 5 days of incubation of the
conjugate at that pB could not completely hydrolyze the conjugate.

OH

DHCho

MPEGSOOO

Scheme. 2.5 Acid Hydrolysis ofDHCho-MPEG5000

: Ortho Ester
• Orthoester is a more pH-sensitive linker than vinyl ether and is also found to be relatively

· stable at physiological pH.

The acid-triggered hydrolysis of orthoester involves a

: stabilized diaJkoxy carbonium ion (Scheme 2.6) that further degrade to an alcohol and an
ester compound (81).

HlO,slow

Scheme 2.6 Hydrolysis mechanism of Orthoester

Guo and Szoka synthesized a pH sensitive

'POD~ lipid with a diort:hoester linker (Fig

2.6) and incoporatedit into liposomes. (Hydrolysis Se.h eme 2.7)
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.

.. .

Pig. 2.6 Structure of the 'POD' lipid

~0X

R,-()H

+

HO

.

OH

+

R2-0H

0~
0

Scheme. 2.7 Acidic hydrolysis oforthoester based lipid

The incorporation of POD and DOPE in a ratio of 1/9 in liposome membrane stabilizes
the liposome at physiological pH but at low-pH POD hydrolyzes to shed off the PEG
coating to wnvert the DOPE-rich liposome membrane to a hexagonal phase.
The stability of I 0 mol % of POD incorporated into liposomes at alkaline pH 8.5 was
about 2 weeks. In vivo studies on POD/DOPE liposomes suggested a half life of200 min

(83) while the half life. ofDSPE-PEGIOOPE lipoSomes \\'35 ~ 295 min. Stability studies
of POD conjugate suggested that it remained intact for 3 hours at 3 7°C while complete

5.4
: hydrolysis was observed at pH 5 within 1 hour (81 ). The POD liposomes resulted in
: extensive content release and aggreagation at pH 5*6 (81 ). The release of contents from
the liposomes contains two phases: a lag phase when the contents slowly leaks through
the liposome membranes followed by a burst phase when sufficient POD hydrolysis
triggers the lamellar-to-inverted hexagonal ,phase change of the liposomes to quickly
release most of the contents.
The POD has also been exploited in intracellular delivery of plasmid DNA (8 1).
Stabilized plasmid-lipid particles (SPLP) composed of OOTAP~ OOPE and plamid DNA
and 1.3 mol% POD resulted in liposome collapse within 110 min. at pH 5.3 whereas the
pH*insensitive lip()somes witboutPOD remained stable at 1owered pH.
Instead ofdiorthoester, masson et al (84) designed five and six membered ring orthoester
based lipids (Fig. 2.7) and incorporated them into lipoplexes. The conjugates were stable
for 8everal days at pH 7.5 but the long tenn stability of lipoplexes composed of the pH
sensitive orthoester lipids was not determined.
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Fig. 2.7 Ortho ester lipids designed by Masson et aL

Hydrazone Linker
Hydrazone presentS another linker (Fig.. 2~8} that has been exploited by researchers for

pH-triggered drug/gene delivery.
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Fig. 2 ,8<Chemical structureofhy.drazone tinker.

Aissaoui .et al (95) synthesized a series of cationic guanidinium based lipids- (Fig. 2.9)
' where acylhydrazone iinker was used to link head group with a steroid. lipid tail. All .the

lipids were demonstrated to undergo. acid-catalyzed hydrolysis; It was observed that
unsatlltated compoUnds BGBH,chotest-.4:0enone and BGTH·cholest•4~enone showed
s]o\Yer hydrolysis kinetics with halftives t.9 and 2j days at pH 4.8 than the saturated
8GBU~cholestimone

and BGTH~cho)estanone compound~Lwith halflives oft.2 and 1.3

days reSpectively. The lipoplexes composed of bis-guanidinium bis~(2~aminoethyl)arnine
hydrazone (BGBH)-chcdest;,.4-eri()P¢/l)NI\ m¢diated efficient gene transfection in

mammalian cells and.in mouse airw:ays.
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1~19, BG8H~hoie$tano~

1-20, BGBH-cholest-4-enone

H'N
2 \..._

.

11NH
HN
~ .-

.·

0

U
~
N- ........., ---~-N

(

-~

. .

NH

HN~NHz

, 3. CH~OzH

1-21, BGTH.,Cholestanone

i-22, BGTH:.Cholest-4--enone

Figure 2.9 Chemical structures of gliarii(liniurihbased cationiclipids.
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Shedding of PEG Coating by Hydrolysis of Hydrazone Linker

. eased on the

review of

pH~sensitive

linkers

we propose a strategy to improve

intracellular uptake ofliposomes by shedding the PEG coating that hinders the .interaction
of tumor. The PEG coating

can be

removed ~Y placing a hydrozone linker between lipid tails and polar head group~

Whil~

ofliposomes with the cell surface in the

V1~inity

hydrated PE(J . ~oating around the liposome st~rfac~ hinders the hydrophobic: interactions
with serum proteins and

immun~

.ceJls in blood circulation, the removal of the PEG

coating will lead to increased interaction of the liposomes with cancer cells at the acidic

tumor interstitium.
One C()tnmon feature of all cells is ne,gatively charged celt surface. The presence. of

negatively charged lipids such as .phosphatidylserine (PS) and phosphatidyJ inositol {PI)
impart negative charge on the cell surfac~.

Vance and Steenbergen in 2005 (85),

determined.that approximately 15 % of.PS and PI were found in rat liver .cell membrane.
Additionaly the ~ell surface has an abundance of extracellular matrix (ECM} that contains

proteogJycans and glycosaminogtycans which provide

a majority {)f negative charges at

the cell surface (Fig. 2.10). Additionally, tumor surface charge was found .to be even
more .rtegative than normal cells (88). The glycosaminoglycans in the ECM include
heparan sulf~te. chondroitin sulfate and hyaluronic acid.
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Fig. 2.1 0 ExttaceUuraf matrix over cells

Work of Mounkes et al (86) and Mislick et al (87) established that heparin!heparan
sulfate and chondroitin sulfate play a crucial rc)ie in intracellular uptake of cationic
• lipoplexes.
Based on the aforementioned, we propose a pH..sensitive liposomal system that will act
as a stealth liposome at physiological pH and convert to cationic liposome at lowered pH
in the tumor environment for increased intracellular uptake (Fig. l.Jl ).
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~
TUIIlOl' Iutentiti:wll
Weak Acidic
(pH 6 .!\-7.0)

CeU

Fig. 2.11

Concept of design of hydrazone based pH -sensitive liposome

To achieve the pH triggering a novel PEG-lipid conjugate containing hydrazone linker
can be introduced in the liposome membrane as mentioned earlier. The hydrazone tinker
is expected to hydrolyze at Iow·pH environment to shed off the PEG coating and leave a
hydrazide lipid which cmt acquire positive charges on liposome surface in the weakly
acidic tumor interstitium (Scheme 2.8).

The formulation design can also contain

6l'
'

lxcessive positively charged lipid (elg J)()TAP)to overcome the limited mol% ofPEG~
~pid conjugates that Call be incorprirated into the liposaine membrane.

·. ·.·.

R1
R3
\
H
/ ( " ) ..
N-N
. . \C_,_O-H

.~

I

:.'
\ R$
'+

R'-)

H

I
Rt

\

I

.

.

N-NH,.

-

+

Ri

Scheme 2.8 Acid HydrolysiS of Hydrazone
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2.1 Materials and methods. 1,2:..Di..O-hexadecyl-rac-glycerol (DHG) was purchased
from Bachem.

Ethyl B~oace~te. sodium hydride (60% dispersion in mineral oil).

hydrazine hydrate (80%), Iodobenzene diacetate {BAlli), 2,2,6,6-Tetramethylpiperidine1-oxyl-4-amino-4-carboxylic acid (TEMPO) were acquired from Fisher Scientific.
Polyehtylene glycol 2000 monomethyl ether was obtained from Sigma Aldrich. All other
organic solvents were purchased either from Sigma, Fisher or VWR.

2.2 Synthesis

2.2.1 Synthesif of ethyl-2-(2,3-bis(hexadecy/oxy)propoAy)acetate (DHG Ester)(1.9.2,
Scheme 2.9).

1,2-Di..Q..hexadecyl-rac-glycerol (DHG) (1.5 g. 2.77 mmo1, 1 equiv.)1

(2.9.J, Scbe• 2.9) was dissolved in 20 mL oftetrahydrofuran. Sodium hydride (60%
in mineral oil) (0.44 g, .11.08
round bottom flask.

mmo~

4 equiv.) was washed with hexane in a separate

Hexane was removed and DHG solution was added to sodium

hydride at the bottom of the flask. The reaction was allowed to run for 30 min. under
argon at room temperature. Temperature was lowered to OOC and Ethyl Bromoacetate
(I .85 g, 11 .08 mmol, 4 equiv.) was added to the reaction mixture. The reaction mixture

was stirred under argon for 6 hours and monitored by TLC (silica gel 60 F254, EMD
chemicals, Germany) developed with ethyl acetate/hexane = l/ 10. Then H~ was added
and the mixture was washed with diethyl ether. The combined organic layers were dried
over sodium sulfate, filtered, concentrated in vaccum and purified by silica gel
chromatography w ith a gradient mobile phase of Ethyl acetate/Hexane (1120 to 1/1 0, vlv).
(Yield 51%) (MALDI +ve ion mode: 650.6 (M+Nat, 1HNMR (600 MHz, CDCh) (Fig.
2.12):

o0.83-0.87 (t, 6H, 2 C!b(CH2)w ), 1.18-1.32 (m, 52H, 2 -OCH2CH2(CH.,)uCHJ),
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1.53 (m, 4H+ 2 ·OcH:!GHi(CJi2)uCHJ); 3.38-3.68 (11tt 7.1:1~ C~J(~Hi)t4Ct!...,OC!hCHO
,CH.,); 4.1-4i26{m,4H~ CffiCOOQfu);
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+

CHa(CHz)IS-0
2~9.1

OH
NaH

J~~c,
0

O-(CH2) 2 -.-O_jj__CH2Br

NH2NHz,
Ethanol Reflux

180-

2.9.2

85 °C

6h

0

II

O-(CH2)z--O-...&J--NliNHz

mPEGl<)O(>CBz CHO

I

2.9.3

r.t.,
Overnight

0

CHj(CH:z) 1s-·0

O-(CH:z)2

II
-o--·--'.&...-NHN..

H

C-PEG2ooo

2.9.4

Scheme 2.9 Synthesis ofDf{G-Hz-PEG conjugate
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2.1.2 Synthesis ,of2-(2,J-bis(hexadecyloxy)propoxy)eth)·IHydrarinecatbox)'lnte (DHG
Hydrazide) (2.9.3, $~heme 2.9). Ethyl-2•(2,3~is(hexadecyloxy)propoxy)acetate (2.9.2.
0.48.g~ () .765 mmol, 1 equiv.)was dissolvedin·ethanol at 50°Cunder argon followed by

addition ofhydrazine hydrate (2.3 mmok3 equiv.). The temperature was raised to 80-

850G and ~thanof. was allowed to reflux for ·6 hours tinder argon.

Th~. reaction

mixture

was monitored by TtCdeveloped with .ethanol/ 2%NH40H. The reaction was cooled to

OOC; the separated precipitate was filtered off and washed with· ethanoL (Yield· 100 %),
AccuTOF(M +H)+ 613.5 1HNMR(600 MHz, CDCh)(Fig.l.J3):

(CH2)tsC!::b), 1.2-1.35 (Ill. 52H, 2 ·OCH2CHz(Clb)nCH3)~

8 0.84•0.89(t. 6H; 2J56 (m, 4H, 2 -

OCJ-hCfu(CH2)t3CHJ), 3;38.;3.72 (m, 7H,CHl(CH:!)t4CH,QC!::bC!!O.., CH2). 4A (s.2H,
-NH-.NH,)~9.04

(s, 1H,.;NH-NHzJ
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·· 2.23Synthes;s ofmPEG-2000 Acetaldehyde (2.10~Scheme 2.10).. Polyehtylene glycol
2000 monomethyl ether (mP.EG) (2g) was dissolved in 20 mL of anhydrous toluene and
dried under vaccum. 15 mL of dichJorometbane was added to previously dried mPEG.
TEMP0(0.035g, 0.224 mmol) was added followed by addition ofBAIB 0 & 3.1 mmol).

The reactiort was stirred at room temperature overni~ht under argon. ·The mixture was
then precipitated by addinglSO mL·ofanhydrous diethyl ether. filtered and dried. (Yield
1

. .. .

·. . ..

.

.. .

..

.

.. .

...

.

.

. .

··..

. .

.

56%) HNMR (600 MHz, CDCh)(Fig.l.l4); 6 3.35 (s, 3H), J.50- 3.70 {m. 1 76H),

4.13 (s. 2H)•. 9.7J (s~lH)

TEMPO/

..
BAIB
· ··
· · CHO)
CH c-o
H 3C
. · O-(CH2CH0)44-·· CH2CH20H . . . • H 3CO-{CH2 . :.w- 2 · · ·· ·
·
Ovemtght
1
~L

2.10

Scheme 2.10 Synthesis ofmPEGiooo Acetaldehyde
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. 2.2.4 Synthesis of DHG-Hz-PEG (2.9.4, &he~~te 2.9). Hydrazide activated DHG (O.lg,

0.172 mmol} was dissolved in

~hloroform

followed by addition of mPEG-Aidehyde

; (0.86g, 0.43 mmol). The reaction mixture was .stirred overnight under argon at room
; temperature and monitored by TLC developed with CH30H!CH2CI2 1/9 with 2%
ammomium hydroxide (Fig 2.15).

DHG Hydrazide

DHG-Hz-PEG

Gl
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Fig. 2.1 S TLC showing the formation ofDHG-Hz-PEG lipid
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•H-seasitivity of DHG-Hz<OPEG

'

fhe pH sensitivity of DHG-Hz-PEG was tested by adding 2% acetic acid in the ethanolic
$Oiution of the reaction mixture. The acidified reaction mixture immediately shows the
&pot

characterstic of DHG hydrazide (Fig. 2.16) suggesting hydrolysis of the DHG-HZ·

pEG conjugate (Scheme 2.8).

DHG Hydrazide
DHG-Hz-PEG

Fig. 2. t 6 Acidified hydrolysis of the reaction mixture shows the formation of DUGhydrazide

12
: Sepantioa of DHG-Hz-PEG
; Separation of the conjugate DHG-Hz-PEG using HPLC did not show any peak with C4.
. C8 and C 18 Columns. Neithe.r did silica gel column show any conjugate eluting out of
: the column. Subsequently sepharose-crosslinked 48 gel column ( l em x 23 em*Length x
Diameter) was used to purify the conjugate using pure water as eluent but did not show
the conjugate eluting from the column at pH 7.4 . However, at pH JO.S (pH of water
1

adjusted with

2 N NaOH) the conjugate started eluting out (Fig. %.17). The elution time

was 30-40 min.

DHG Hydrazide
DHG-Hz-PEG

Fig. 2.17 TLC

.
. -PEG eluting out of the column
ofthe eluent showmg
the DHG-Hz
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'The purification results of the DHG-Hz-PEG cqnjugate at different pH conditions using
gel chromatography, indicate that the hydrazone-based lipid conjugate is highly unstable

'at physi()logical pH.
:Torchilin et al (91) have previously synthesized a series of aliphatic and aromatic
·.Aldehyde based hydrozone lipid conjugates. Their findings indicate that the half life of
:the aliphatic conjugates ·were less than 2 min. at pH 55 while the half life of the most
stable aliphatic conjugate was no more than 2;5 h at pH 7.4. Inclusion of aromatic ring
next to the . hydrazone linker yielded very high stability where the half lives were more
than48 hand 72 hat pH 55 and7.4, respectiv~Jy for all the aromatic conjugates.
Our results show that the hydrazone.:.based lipid conjugates were highly unstable at pH
7.4 and therefore not suitable for Jiposome preparation and subsequent anticancer studies.
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Chapter 3: Design, Preparation and Characteriati~n ofpH,.~nsidvc Convertible
Liposomes for Anticancer DrugDclivery
·

. IntrOduction
~ Advanc~s in liposomal tumor targeting have received consideralYie attention for their

potential advantages(I02)(l03}including: high drug to carrier ratio, ability to formulate
lipophilic as well as ~ydrophific drugst targeting to tumor. long circulation halfJifc (I 03 ),
biocompatibility of the carrier and minimal toxicities of the constituent 'lipids. Th~
·advent of •stealth liposomes' have resulted in increased blood circulation. halflife of the

JipoS<>ines(35)and therefore increased accumulation in the perivascular environment by
the 'Enbaru:ed Penneation arid Retention Effect'. However the 'PEG coating. of the
stealth liposome also reduces their interaction with tumor cells (see chapter I, Passive
targeting) and their penetration in solid rumors( I 11 ).
To increase the celi.:.JipoS<>nie interaction and intracellular uptake of the drug .a broad
spectrum of PEG-shedding strategies have been previously introduced ( 104). Of note,
the strategies to shed.the PEG coating from stealth liposomes include the jm:orporation of
pH-sensitive linkers whiCh can hydrolyze in the low-pH environment (see chapter H).
However, lipids containing such pH-sen~itive linkers show either poor stability (see
chapter II~ Separation of DHG-Hz-PEG) at physiological p'H~ or insufficient pH-

7.5

sensitivity to the mildly acidic pfl in the tumor interstitium (see chapter II, Vinyl ether)
(77) (79) (80).

Fur:thennore, poor stability on shelf is another concern for such

hydrolyzable.lip()some_s (127). It is thus desirable to develop liposornes that are stable
both onshel fand in blood circUlation and yet can reniove the PEG coating in response to
lowered pH.
This project proposes a stratew to improve the shelf stability andintrac:ellular delivery J>f
· drug by PEOyJated liposomes. Instead ofusing lipids.w'ith an· acid;.; labile linker we have
developed imidazole-based lipids that can protonate at low-pH as seen in the tumor
interstitium. The proposed convertible Jiposomes containingprotonable imidazole lipids
could convert: from stealth to cationic liposomes in the tumoral interstitium (Fig. J.l).
The conversion to cationic Jiposome is based on protonation of imidazole lipids and
chistering of PEG lipids on the 1iposome surface. The newly fonned cationic liposome
can then have greater interaction with the negatively· charged celt membrane and
extracellular matrix (123) (see chapter II). Because the liposome converts from stealth
to cationic Jipo~ome we have giveri them the term •convertible Liposomes'.
The concept of design (Fig. 3.1) is based on the inherent properiy of the lipids to

segregate into different

phases- based

interaction amongstthem{l24).

on electrostatics and vander waals Ioree of
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~pH

Convertible liposomes
Fig. 3 .I Concept of design ofconvertible liposomes: protonation and clustering of PEG
coating on liposome surface in .response to lowered pH.

The convertible liposomal system essentially comprises of three different types of lipids

(Fig.
the

3~3).

1) a negatively charged PEGylated lipid with two Cl6 hydrocarbon chains as
.

lipid

tail

.

(1 ,2~dipalmitoyl-sn-"glycer<r3-phosphoethanolamine~N-

[methoxy(polyethylene gJycoJ)-2000 (DPPE-PEG, shown by Jetter •p, in Fig. 3~2), 2) an
imidazole-based, protonable lipid with two CI6 hydrocarbon chains as the lipid tail
(shown by tetter 'N' in Fig 3.2), and 3) a Cl8 chain lipid DSPC (1,2-distearoy.J-snglycero-3-phosphocholine). that has no net charge. The molecular stimulus that triggers
the phase separation of the lipids is the acidic pH of the tumoral interstitium. At acidic
pH, protonable "lipids will protonate and acquire positive charge on the ·surface. The
protonated· lipids are attracted to negatively charged PEGylated lipids due to the
electrostatic interaction and vande,r waals force of intera~tion o:wing to the same carbon
chain length (Fig. 3.3), This leads to the fonnation of PEG cluster on the membrane
exposing excess posi,tiye charge on tipo$ome surface. Such a fonnulation will allow for
increased binding with cancer ceUs and higher uptake by the. tumor cells.
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pH-p:toto·n able
Imidazole

DSPC
Fig. 3.3 Three types of lipids (DPPE-PEG, Imidazole lipid and DSPC) comprising the
convertible liposome, Negatively charged DPPE-PEG and protonable Imidazole lipids
interac.t ~t low pH
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Tumor pH

· The trigger of the proposed convertible liposomal system is the pH of the solid tumor.
The pH ofthe extracellular interstitium in solid tumor is between 6.0 to 7.0 .(105}(106)
. ( 107) with th~ pH approaching close to .6.0 at the tumor core. The aCidic pH in the tumor

is due to the heterogeneous network of blood vessels in. solid· tumors which leaves parts
of the tumor without sufficient oxygen supply (Fig. 3.4). The tumor cells in the hypoxic
region are forced. to undergo anaerobic glycolysis (lOS) (109) as a major metabolic
pathway leading to the production of lactic acid and thencethe acidic pH. Additionally,
findings ofSvastova et aJ suggested the role of carbonic anhydrase lX in the ~reation of
acidic microenvirorunent in tumor ( 11 0).

Vascularized
circumference

Tumor core

ilt

Cancer stem

Fig. 3.4 Picture of solid tumor showing heterogeneous and leaky vasculature and hypoxic
region (adapted with pennission from (128)).

The convertible Jiposomal system has tunable surface topography (I 24) that starts as a
stealth liposome and yet converts to a cationic liposome at the pH mimicking the tumor
environment. The principal behind the formulation development is that the con vertible
liposome will remain masked by the Polyethylene Glycol (PEG) shell during the systemic
circulation but the PEG shell will progressively de-shield as it encounters low-pH
environment mimicking solid tumor and thereby exposing excess positive charges on the
liposome surface acquired by protonation of imidazole lipids.
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, In this study, we. have synthesized a series of imidazole based pH-titrable lipids with

increasing pKa values (Fig. 3i5, estimated pKa values· ranging from 5.36 to 6.75) and
incorporated them into convertible liposomes to·. render liposomes with increasing pHsensitivity. The fonnation of lipid domains and the potential of these Hposomes to
associate with and kill cancer .cells at tumOl'-relevant pH is evaluated in Bl6Fl0 (mouse
melanoma) and llela (human cervical) cancer cells.

oi_
.·

H

o . s-{J
N

DHlpKa 553 ± 0.5
.~·

DHMI pKa 6.2 ± 0.5

DHDMl6.75 ± 0.5

0

~i_s-{JJJ

o .
DPL5.36 ± 0.5

Fig; 3.5Structure ofpH..protonable imidaiole lipids

N
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.Materials and Methods

.3.1 Materials. 1.,2-Di-0-hexadecyl-rac-glycerol (DHG) was .purchased from Sachem.
·Torrance~ CA, p-Toluenesulfonyl chloride, Pyridine (anhydrous) ·.from fisher scientific~

· 1.2-Dipalmitoyl-sn-.glycerol fr.om Chem-Jmpex Intemational, Inc., Wood Dale, IL, 1~2-·
dioleoyJ-sn-glycetol,

1,2-.distearoyl·sn-glycero-l-phosphochoiine

(DSPC).

1.2~

dipalmitoyl-sn-:-glyceto-3-phospboethanolamine:..N-[methoxy(polyethyJene slycoJ)-2000
. (OPPE-PEG) from Avanti Polar Lipids, Inc., Alabaster, AL,. 2-Mercaptoimidazole, Triethyl amine from Sigma Aldrich, 4;.Methyl-1 H-imidazoJe-2-thiol and 4;S-DimethyJ.; 1Himid:.tzole-2-thiol from Oakwood Prod~cts, Inc.~ West Columbia. SC, Doxorubicin
hydrochloride from Ontario chetni~als, ON. Canada. All organic solvents were purchased
from Fisher sc·ien.tific, VWR orSigina Aldrich~

l .2 Synthesis of E~ter lipid DPI
J.i~ 1 Synthesis· of sn1--J·((phenylsu/fonyl)oxy}pt'opl!ne-1,2-diJ'I dipalmitote (DPG

Tosylote) (3.1./, Scheme J.l).. 1,2.'-Dipa·Jmitoyl-sn-gJycerol (DPG) (0~25 g, 0.44 mmol, 1
equ·iv),~ was

dissolved in 20 mL of dichJoromethane, followed by dropwise addition of

pyridine (1.82 mL, 22

mmol~

10 equiv). [r'ToltJenesulfonyl chl¢ride(O.J7 g, 0.88 mmol,

2 equjv) was th.:n added to the above solution. The reaction mixture was stirred under
argon at room temperarure· for 8 h, and monitored by TLC developed with
dichloromethane (Scheme 3.1). The reaction mixture was then washed three times with
saturated sodium carbonate sollJ.tion. The· combined organic layers were dried Qver
·magnesiUm. sulfate., filtered, concentrated in vac(lu,m and separated by silica gel

82

chromatography with dichlorornethane as mobile phase to yieid the product. (Yield 56

%), DART {M+Ht 551.5
J.2.2 Syntliesis of (sn)•J-((IH•imidar.ot-2~);1)ilrio)p~;opane•1;1-diJ'I-:-dipalmitate (DP/)
(J./~2, Scheme J.l)~ 2~MercaptOimidazole

(0.1 g. 1.0 mmol, 5 equiv.) was disSolved in

- DMF and a smaJ.I amouritof Dichloromethane was. added, Triethylamine (0.14 mL, 1.0
mmol,

5

equiv~)

was

added

to

the above solution fQUqwed by

((phenylsuifonyl)oxy)propane-1,2~iyldipalrnitate

reaction was allowed to run

fo~

48 h at

(sh)-3-

(0.15 g, 0.2 mmol, I equiv) and the

ss·c under argon.

The solvent was evaporated

and reaction mixture was re-dissolved in ethyl acetate and washed thrice with saturated

sodium bicarbonate solution. The combined organic layers were dried oyer s.odiurn
carbonate, filtered, concentrated in vacuum and separate<! by silica gel chromatography
with Ethyl acetate I Hexane

= 3n

as mobile phase to yield the product (Yield 9- %),

DART(M+Ht 65l.5 (Fig. 3.6), 1H-NMR (600 MHz, CDCh) (Fig. 3.7): o0.87 (t, 6H. 2

CH 3(CJ·b) 15-),

o 1.15-1.35 (m, 52H, 2 -OOCCHiCI-h(Cfu)hCHJ), o 158 (t, 4H, 2 -

OOCCH2CH7(CH2) 13CH3),

o 23

o 3.38, 3.66 (q,
o 7.08 (d, lH,

(t. 4H, 2 -OOCCJ:hCfh(CH2)t3CI-h),

2H, -l::hCSCNH-), o 42, 4.4 (q~ 2H, CH3(CH2)t4COOC.l:b-),
H2CS0==NHC='CH-NH-)~.o 8~04 (d,

1H9 H2CSC=NHC=CH~NH-)
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. 3.3 Synthesis ofEther lipids DHI; DHMI and DHDMI

, J.J.l Syntllesis of 1,2"-Df...O·hexadec)'l-rac-g/ycet)•/ tosJ'Iate (DHG ToSJ•/au) (3.2.1,
Sclteme 3•2). 1,2-Di;.Q...hexadecyl~rac;.g)yc~rol (DHG)(2.43 g, 4,5 mmol, 1 equiv}, was
· dissolved itt20 rnL ofdichJoromethane~ followed by dropwise addition ofp)'ridine{l8;6

mL, 225 inmol, 50 equiv). pToluenesulfony1 chloride (1.71 g, 9.0 mmol, 2 equrv) was
then added to the above solution (Scheme·3.l). The reaction mixture

was stirred under

argQn at rorim ,temperature for 8 h, and monitoted by TLC (silica gel 60 F254, EMD·
chemiCals, Gennany) developed with dich1oromethane. The reaction mixture was then
washed three times with saturated sodium carbonate solution. The ~ombined organic
I~yers

wer.e dried over magnesium sulfate~ filtered, concentrated in vacuum and separated

by silica gel chromatography with dichlotornethane as mobile phase to.yield the product.
(Yield 65 %);, DART (M+H)+ 695.5~ 1H·NMR(600 MHz, CDCh. -6 ppm): 0.87(t, 6H. i

CI:b(CH2)w), l..i8-L3l (m, 52H, 2 -OCH2CHi(CH~)13CH]), 1.4"6 (m, 4H, 2 OCH2Cfu(CHz)t3CH3),

2.44

CH3(CHz)14CfuOC!:bCHQ.;),

(s,

JH,

-(C6H4)Cfu),

331-3.61

{m,

.5H,

o4.14 (m, 2H, ..C!bSOt~), S.7.3l(d, 2H, aromatic protons

ortho- to ~S02~), and fJ7 .78 (d, 2H, aromatic protons ortho-. to·CH3-)

3.3.2 Synthesis of (sii)~2-((2,J-bis(hexadecy/oXJ')prop}'l)thio)~JH -iinldazole (DHI)
(3.2.2, Scheme 3.2)~ 2- Mercaptobnidazole (0.66 g,. 6.61 mmo~ 5 equiv.)·was dissolved

in DMF and

;:t

small amount of Dichloromethane;was added. Triethylamine (0.92 mL,

(;.61 mmol, S equiv.) was added to the. above solution followed by 1,2;;.Di•O-hexadecyl-

rac~glyceryJ tosylate (3;2.1) (0~92 g, 1.32 mmol, lequiv)and the reaction was aUowed to

run for 48 b at 5'5''C under argon (Scheme 3.2). The solvent was evapotated and reaction

87
mixtUre was re-dis~olved in ~tbyta<;etate and washed with saturated sodium bicarbonate
solution (3x). Th(! coinbirie(f

organic layers were dried over sodium carbonate, filtered.

concentrated in vacuum and seperated·by .siiic~ . gel chromatography with Ethyl .acetate /
Uex:llJ)e = 3(1 as :ti10bile phase. (Yield 26.%), QART(M+Ht 623.5 (Fig. 3-.8). 1H-NMR
(600.l\1Hz, COCb) (Fig•. 3~9):

o Q;87 (t, 6f{,.2 C!.!J(CH2),~~), o 1J9-Ll2 (m, S2H.2 """'

OCHiCH2{Clli)13CH3)~

6 1.55 (m, 4H, 2 "-OCH2CH.;(CH2)13Cl-h, 5 3;22~ 3 .65 (d.t:f2H, •

H.,CQCJh(CH2}1.tCH3),

~;: 3..38.., 3~6

H2COCfu(CB2)t4CH)),

·~

3~73

(d,d 2H, (m,

1H,

,lliCSCN.f:l~)~

o ~.44, lSS

CH3(CH2)rsOCH~).

. HtCSC=NHC==CH-NI-i-), o7.21 (d~ 11:1. H2CSC=NHC=CH.;NH~) •

o

(m,

4H. 2 -

7;02 (d,

lH.

88
CHz(ClJ~I5:=J
CH2(Cif2lts

.~

0

L

O=a-f"\
. · . ·.·· CH

+

~· '

.I

Cl

OH
Pyridine
8 h,t.t.

1
CHz{CH2)u·o=t
· ·.. . .
CH2(CH2)ts-o

0

II .
·. .-0-

o
· .·
-Cfi3

·.2

"·.:t

J.s.

0

H

· ..

N

·• R1

N

R~.

Hs-(X

:::::::

TEA
~o 0c
48 .h

==t_
·..

·. ·

Nx··

.·H .

R

s-( 1. .
N

· ··R"2

DHI
R1 = H, R.2 = H
(3~.2.2)
OHMI R1 = Cll3, R2 =1-1 (3.2.3)
DHDMI R1 = CH3 ~ R2 = CHi (3~2.4)

Scheme 3.2Synthes1s ofDHI, DHMI and DHDMI
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3.3.1 Synthesis of sn·2-((i,J-bis(hexadecyloXy)propyl)tllio)w5.;.meth)'I~JBw imidazole
(DHMI) (3.2.3, Scheme J.2).

4wMethyl-1H-imidazole-2~thiol

(0.75 g, 6.61 mmol, 5

equiv.) was dissolved in DMF and a small amount of Dichloromethane was added,
Triethylamine (0.92 mL, 6.61 mmol, 5 equiv.) was added to the above· solution followed
by 1,2-Di-0-hexadecyl..tac-glyceryl tosylate (3.2.1) (0.92 g, 1.32

mmol~

1 equiv) was

then added to this solution _and. reaction was allowed to run for 48 h at· 55"C under argon

(Scheme 3.2). The washing and purification was the same as mentioned in 3.3.2. (Yield
22 %), DART(M+Ht 6375(Fig.J..l0). 1H·NMR (600 MHz, CDCh)(Fig. 3.1 1): o 0.87
(t. 6H, 2 C.lli(CH2 ),5·)~ c5l~l9-1.34 (m~52H, 2 -QCihCI:h{CH,)uCHJ), o 1.53 (m,4H, 2

-OCH2Clli(CH2)t3CH3), 52.31 (s; 3H, -HzCSC=NHC=CH-C!h), o324, 3.66 (d,d, 2H~ fuCOCH2(CH2) 14CH3),

o 3.4,

3,6 (d,d 2H~ "' _lliCSCNH~).

H2COClb(CHz)t4Cll3), S 3.73
H~SC=NHC=CH-NH-)

(~

o 3.44,

lH,. CH3(Cth)1sOCH-'),

3.55 (m, 4H, 2 •

o

6.81 {d.

lH,
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3.3.4. Synthesis .of sn~2-((1,J-bis(hexadec)"'oxy)prop)'l)lhio)-4;5-iit~tii)'I-JH~i,idal.()/e
(DHDMI) (3.2.t/, Scheme 1.2). 4.:Methyl-lH-ilnidazofe-2~thiol (0.84 g~ 6.6 J mmol, ~·

equiv.) was dissolved in DMF and a small amount of Dichloromethane

w~s

added.

Triethylamine (0;92 mL, 6.61 mmoJ, S equiv.) was added to the ~bov¢ S0lution.foJiowed
by i;2-bi.:O-hexadecyi~rac~gtyceryl tosylate (3.2. 1) (0,92 g, 1.32 mmol; I equiv) and

reaction was allowed to run for 48 hrs at

ss·c under argon (Scherile 3 ~2). The washing

and purification was similar as mentioned in. 3.3;2 {Yield22 %), DA.RT (M+Ht 651.5

(Fig. 3.12), 1H-NMR:(600 MHz, CDCIJ) (Fig. 3~13): .o 0.87 (t, 611,. .2 Clb(CHz)l5~).

o

L 19-,1.34 (m, 52H, 2 -OC~2CH2(Clli)tJCH3)~ o1.53 (m, 4H, 2 -OCH2C.th(CHz)uCH3),

52.11 (s, 3H, -H2CSC=NHC=Cft..,C.lli)•.o 2.17 {s, 3H,. -H2CSC=NCC.lli); o3 . 14; 3.65
(d,d 2H, ~!hCOCH2(CH2)a4CH3), o.3.29, 3.59 (d~d 2H~ - !bCSCNH~)•. o3A2,. 355~ (m,
4H,2 .;H2COGI:h((:'H2)t4CH3), 6 3;73{mi lH, CHJ(CHz)t,OCR·)
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;

95

-!

-

-I
&
...
....

-·

~--

.....

-~

-·

·-~

·e-.0

u:
••

96

•·'

i

.

~·

!·-

r.o

-

0
.

..,

0

j
!

-·

~

""

I

..

!

C;

!

0

"'

,

..

;97
3.4 ,Calculation of p:K a. The pka of the lipids (DHI~ · OHMJ, DHDMI and .DPI) was
calculated using ACD/pKa DB softWare (Advanced Chemistry Developmet, Inc.,
!

Ontario, Canada)(l26).

3.5 Preparation otl..iposomes. Liposomes were prepared by lipid film hydration and
extrusion (98). Chloroform solutions of appropriate lipids (Table 3.1) were mixed in a
25 ·mL round bottom flask~ Chloroform·was evaporated in a Buchi rotavapor and funher
dried in vaccum oven for 3 hours at room temperature to. remove traces of the solven~.
The lipid film was then hydrated with HEPES buffer {pH 7A,. 5 mM HEPES) with

or

without 140 mM NaCI using intennittent agitation to obtain a suspension of · 7.5 mM

total lipids.

For pH dependent· change of

Zeta

between convertible and model Jiposomes and

potential measurements•. interaCtion

nsc

experiments liposomes were

prepared in () mM NaCJ whiJe for the cytotoxicity and doxorubiein uptake experiments,
140 mM . NaCl was used to prepare liposomes. The Hposorne suspension was freeze·
thawed (alternate immersion in dry ice/acetone and water bath at 40 °C) eleven times and

extruded sequentiaUy through 40Q rim and 200 nm poJycarbonate membranes
(Nucleopore Corp., Pleasanton, CA) using .a Mini.extruder (Avanti Polar Lipids fnc:.

Alabaster, AL) at7o• :C to yield the liposome preparation. The particle diameter and ~·
potential of the preparations were measured by photon correlation

s~ctroscopy

(Zetasizer ZS90, Malvern. Instrum-ents Ltd., UK).
The average liposome sizes for all the formulations studied ranged from 200-270 nm

98
3.6 Composition of*Convertible.. Control·and 1\fodd lipc>s()me$
Table J.l Lipid Composition of Convertib1e (I, II, JII}and Control (IV) Liposomes
.

.

Mol%
Liposome

Preparation

No.

om
I

II

DHMI

DHDMI

25
25

HI

IV

25

DSPC

DPPE-

PEG

70

5

70

5

70

5

95

5

*The ester basecl ifJiidazole lipid (DPJ) was not used for liposott1e prepranion and
subse.quent experiments because oflow yield and expensive pr~cursot lipids.
.

Model liposomes (118) (ll9), that ·mimic the lipid composition of biomembranes were

prepared with the lipid <:Qmposition 50 mol .% POPC, 20 mol % POPE, 5 mol %POPS,
lO mol % L-a-PI and 15 mol %cholesterol
3.7 pH dependent change of Zeta potential. The pH of an aliquot (lmL) of a liposome-

suspension·(see section 3.5) was adjusted \\lith acetic acid ( 5·.mM, final pH con finned. by
pH meter) immediately before taking zeta potential .measurements. The zeta potentials

were m.easured at 37 °C by electrophoresis mobility under applied voltage using Zetasizer
ZS 90 (Malvern Instrument, Malvern, UK).

99
3~8 lnt~racdop betw~en ~oavertible and model liposomes. Liposome suspensions of

pH.;serisitive liposomes

•~ II~ Uland

IV (see section 3.5) were ·mixed with equa1 vol\,lme

of model liposome (see section.3.S} and pH was adjusted.with acetic acid ·(5 mM, final

pH confinned by pH meter). The liposome mixture was incubated for. one hour at 37 °C
and average sizes were measured at 370C by dynamic light scattering \ISing Zetasizer ZS
.9 0 (Malvern Jnstr\lment, Malvern, UK).

3.9 Differential Scanning Caiorimetry of liposome formulations I.and IV. A VP-

DSC Instrument (MicroCal, LLC, Northampton, MA) Was· used for the differential
scanning calorimetry (DSC) studies. DSC scans were performed. oil vesicle Suspensions
of0:5 mL sample volume containins 2.5 mMtotal lipid at pH values 7A and 6;0. The
thermograms of vesicle ~uspensions. were acquired ftom35°Cto 70°C at a scan rate of 5°
Clh. The excess heat capacity curves of samples were normalized by subtraction of the

thennograms-.o f the buffer acquired simultaneously under identical conditions.
J.lO Loadingofdoxorubi~in (D()X) in Jiposomes
3.10./ Doxorubicin loading by ammonium sulfate gradient. Earlier in the study, the

remote loading of doxorubicin into liposomes were .driven by a transmembrane
ammonilim sulfate gradient according to reference .(99) (100) with minor modification.
Briefly, chloroform solutions of appropriate lipids (Table 3.1) were mixed in a round
bottom flask. Chloroform

wa.s evaporated

in a Buchi rotavapor and further dried in

vaccum oven for 3 · hours ·at room temperature:to remove traces of the solvent. Each lipid
film was hydrated with 250 mM ammonium sulfate solution in water and agitated

intennittently to fonn·a liposomesuspension. ThepHofthe ammonium sulfate solution

100

was adjusted to 7.0 with ammonium hydroxide solution.

The resultant liJ)9some

suspension was freeze/thawed (dry ice/acetone, water bath at 40 °C) eleven times and
extruded sequentially through a 400 run arid a 200 run poJycarbonate membrane
(Nudeo.pore Corp., Pleasanton. ·CA) using a Mini~extruder (Avanti Polar Lipids Inc.,

Alabaster; AL) at 70 °C to yield the Iiposome preparation.
transmembran~

To establish the:

ammonium sulfate gradient, the extruded Uposomes were separated from

unencapsulated ammonium sulfate by a Sephadex G-25 column (Sigma, St. Louis, MO)
equilibrated with isotonic HEPES buffered saline (5 mM HEPES, 140 mM

NaCl~

pH

7.4). One volume of 0. 75 mg/mL DOX in the same isotonic HEPES buffered saline was
added into 2 volumes of liposome suspension (lipid concentration =· 7.5 mM) and
incubated for 1.5 h at 70 °C. The liposome preparations were then passed through
Sephadex G.-200 column eluted with isotonic HEPES buffered saline to separate the
liposomal-DOX from unencapsulated DOX.

3.10.2 Doxorul!icin loading by manganese sulfate gradienL Later in this study, the
"loading of doxorubicin was driven by a transmembrane manganese sulfate gradient ( t 01)
with minor modification. Lipids film was prepared as mentioned eariier (see section

3.5). Each lipid film was hydrated with 300 mM Manganese sulfate solution prepared in
HEPES buffer (pH 7.4t 5 mM HEPES, 140 mMNaCI) arid agitated intermittently to get

the Iip·o somal suspension. The resultant liposome su~pension was freeze/thawed (dry
ice/acetone, water bath at 40 °C) eleven· times and extruded sequentially through a 400
nm and a 200 run polycarbonate membrane (NucJeopore Corp., Pleasanton, CA) using a

Mini·extruder (Avanti Polar Lipids Inc., Alabaster, AL) at 70° C to yield t1te Jiposome
preparation. To establish the transmembrane manganese sulfate gradient, ·the extruded
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lip<)somes Were separated fr<>m unencapsulated ammonium sulfate by a Sephadex (j..2s
column (Sigma. St. Louis~ MO) equilibrated with isotonic HEPES- buffered saline (S mM
HEPES, 140 mM l\laGI~ pH 7.4). l volume of 0~75 rnglmL OOX in the .same isotonic.

HEPES buffered saline was added into 2 volumes of liposome susl?ension (lipid
concentration = 7.5 mM) and incubated for 1.5 h at 70°C. The liposome preparations

were then passed through· Sephadex G:-2()0 column eluted witl:l isotonic HEPES buffered
saline to separate the :liposomai-OOX from unencapsulated OOX,
3.~11

[)cterinination of DOX concentration .and encapsulatio,r efficiency. An aliquot

of a D()X'-Joaded liposome formulation was lyzed with 90% ist>propanol containing
0.075 M HCI (125) foiJowed by quantification of the released DOXby Spectroflurometer
(Shimadzu, rf5301 pc. Ex.= 484 nm, Em.= 587 nm). The OOX in the corresponding

liposome formulation before purification was quantified in parallel. The Encapsulation
Efficiency(EE)ofthe liposome formulation was then calculated usingtheformula:
.

.

EE=

. DOX in purifed lipo.m me fi)rmulatian .
DOX inliposOliJe formtllation before purification

x

JOOolo

DOXencapsulation by MnSO-t yielded an EE40-45% for all the liposome fonnulations
while the encapsulation by (NH.)2S04 yielded an EE ~· 12 %
3.12 Dc)xorubi~in retention studies.. Retention of OOX in Jiposomal fonnulation J was

determined by equiHbrium microdiaJysis using rapid equilibrium dialysis device (Thenno

Scientific, inserts with membrane, MWCO = 800() Da) according to manufacturer's
recommendations. The pH ofliposome fonnulatlon of OOX (see section 3.10.2) was
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adjusted with MES buffer (pH 5.937 50mM~ 145niM NaCI). Preci~ly~ 40, 100 al1d 500

f.!L of theMES buffer was added to l mL ofliposome suspension roadjust the pH to 6.97.
6.5 and 6.05 respectively.

100 JJL of 1iposome SIJSpension was. add-ed to the sample

chamber while 300 fJ.L of buffer was added to tile bl).fer chamber. The percent DOX
retained in liposomes at different time points was calculated using the following
equation.

% DOXretained

Where, Vb

= Volume

= 100 x{l- (Vb+vs)(Cb))

of buffer chamber, Vs

CdVd

=

·.

Volume of sample ~harnb(r, Cb

=

concentration of DOX in. buffer chamber, Cd = initial Jiposomaf DOX concentration
added to sample.chamber,Vd = initial volu~eofsample .chamber
3.13 Cell (ultore (onditions. The 816-FiO (murin~ melanoma) cells and Hela (human
cervical cancer) cells were purchased from American Type Cuiture Collection
(Rockville~

MD). Bl6..FJ O cells were maintained in DMEM media supplemented with

lO% feta1 bovine serum, J% Glutamine and I% peniciUin-streptornycin. Hela cells were

maintained in EMEM media supplemented with IO%fetal bovine serum, 1% Glutamine
and f % penicillin:-streptomycln. Cells we~ cultured with complete medium at 37oc in a
humidified atmosphere of S% CO:! in air. ·Cell concentrations wete determined with a

cell" coulter counter.
3.14 MTS cytotoxicity assay on B16FlQ alid Hela cells. f3J6.;FJO cells
cells/well) and Hela

f- 20,000

cells (:- 80~000 cells/well) we~ seeded on 96·\VelJ plates and grown

overnight in complete- medium. The cells ·were then .washed w ith ·pas·and treated with
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tOO !!L o(either complete or serum free media containing free DOX. Liposornal.DOX at
a dosage .of 0.1~ 1.0. 10.0 pg OOX per mL and empty liposome fonnulation 1.
The pH of the media (10 mL) was adjti$ted with glacial acetic acid (Table J.2)and final

pH was conflimed with pH meter.

Table3.2 Adjustment of pH of the media wi.th glacial acetic·acid
Media
(lO mL)

Glaciat·AceticAcjd btL)
pf{7~0

pH 6.5

pH 6.0

OMEM

65

13

20

DMEM

7

17

20

05

2

s

05

3

6

(Serum F~ee)

(Cornol¢te Media)

EMEM
(Serum Free)

EMEM
(Complete Media)

Each test was perfonned in quadruplet Cells were incubated for 3 h and J2 h at37oc

and 5% CO:!.

After incubation for 3 and 12 hours respective·ly, the medium wAS

removed, and the cells- were washed three times with 100 pL PBS buffer and
supplemented with 100

,.uweil of the cornpJete medium and 20 J.!UW.¢11. of ~tTS'•based

CelJTiter 96® AQi.le0\8 One S~lution Cell Proliferation Assay Reagent (Ptom:ega Corp.,
WI, USA) and incubated at 37°C for2 h. The absorbance at 57(1 run w~s. measured using
a micfo.plate reader(Berthold Tristar, LB 941 ).

10-t

The cells thatare not treated by any formulations were grown at pH's 7.4. 1.0. 6.5 and
6.0 and their viabilities were detennined by MTS assay to rule out significant cytotoxicity
caused by the change of pH in the media.

'

3:: JS Quantitation ()(~ellul~r uptake ofdoxorubicin with now cytomdry. Bl6~FJO
cells (- 6'00,000 cells/well) wete seeded on 6.-well piates and grown overnight in
co~plete

medium.. The cells were tlten wa5hed with -PBS and treated with 2 mL of serum

free media containing either free

pox or DOX loaded liposome formulation II at a

dOsage of 10 flg DOX per mL. The pH of the media was adjusted with glacial acetic acid
(Table 3.2). Cells were incubated for 4h at .37°C and 5% COt. After -incubation cells

.,

were detached with detach in (Oenlantis; San Diego; CA), centrifuged and res\lspended in

PBS before taking measureme.nt in .FL2-H channel in FACScan (Becton Dickinson, San
Jose, CA. US.'\).

Results and Discussion

..

"

3~16 Design ofimada:zole-basedlipids. We· have choserlimidazole head group in our

lipid design due it's unique properties. The Nl position ofimidazo1e moiety is basic and
.p rotonates at mildly acidic conditi()ns (130). AdditionaJiy, addition ·of methyl group at
the C4 and C5 position of the imidazole moic~ty gives the..flexibility to tune the pKa of the
molecule to a higher value (Table 3.3).

When incorporated into liposomes. the

protonation of imidazole at low pH pn>vides positive c-harges .to these · lipids which
i

interacts with. neg~tively charged PEGylated lipid (DPPE-.PEG).

To further aid this

interaction, we ba.ve chosenG16 chains as lipid tails for the imidazole lipid which renders
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additioru!J force of attraction (Vander Waals) with the Cl6 cha·in DPPE-PEG owing to
same chain length.
3.17 ·Synthesis of imidazole-based, pH-t~tratable, lipids. The synthesis of both ·ester·

and ether based lipids were earned

out

to yield

a ~fies

of pH titrable lipids. The

synthesis was based on ·firSt the tosyl activation of the commercially available lipid

(DHG J or (DPCJ) with para tolpeJ1e sulfonyl chloride and·then substitution of the tosyl
group with the imidazole moiety using mercaptoimid~zole compounds (l J2) (l J3).

Tosylate is a good leaving group and therefore was exploited for the conjugation oflipid
with the imidazole compounds.. the high temperature conditions were maintained and

DMF was added to the reaction mixture because of the- limited solubility of
mercaptoimidazole in dichloromethane. The-reaction time

was optimized for best yield

and at the same time fewer side products.
3.18 Lipid pKa calculation. The pKa ofthe lipjds{DHI. DHMDI, DHDMI and DPI)

were determined by ACD/pKa software.

Catcuiadon was used rather than the

experimental methods for pKa detennination as these lipids assemble in aqueous media
and therefore it,s bard·to.trace each molecule. Additionally pKa .o f a lipid molecule is
sensitive to its lipoSQmal environment. W,e calculated this. but later did the:zetapotential
measurements of lip(>sornes composed of these lipids was measured at different pH

conditions to ,monitor the protonation process which is more rilevantto the function of
these lipids. The im idazole•based lipids showed estimated pKa ranging from 5-36 to 6.75
(Table 3.3).
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Table 3.3 Calculated pKa of Imidazole based Lipids.

3~19

Lipid

pKa

nm

5.53 ±.0.5

DHMI

6.2 ±0.5

DHDMI

6.75" .± 0.5

DPI

5.36 ± 0.5

Zeta potential measurements. The ability of the imidazole lipids .to protonate at

.mild .acidic condtions wneri incorporated in liposomes has been previously demonstrated
( J16)~ moreover their efficiency as carriers for gene transfer has also ·been ~xamined at

acidic pH (114)(117).

The convertible liposomes (I. II, Ul).prepared and tested herein, show increase in their
zeta potential with increasing pKa of the corresponding imidazole lipids. The liposome
formulation l:shows an increase in average zeta potential value from ..;5.43 mVatpH 7.4

to 2.72 mVatpH 6.0 while formulation n shows ;zeta potential increase from · 2.5 mV to
5.04 mV (Fig• 3~14 (a), (b)). The liposome fonnuJationlll starts at ...0.93 rnV and reaches

12.99 mV value at ;pH ~.0. The zeta potential change of the control liposomeJV did not
show signi'tlcant <:hange in the zeta potential values from pH7.4 to pH 6.0. The increase

in t¢ta potential values ofthe pH tunable liposomes is indicative of the protonation ofthe.

imidazole lipids, moreover the increase in zeta potential values is consistent with the fact ·
that liposomes with higher calculated pKa. ofthe imidazole. lipid show high initial and
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·final zeta potential values, suggesting the protonation. of more ·number of the imidazole
lipids with increasing pKa of the lipids.
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Fig. J.l4(b) Change of zeta potential values Qf liposotne fonnulations (I-IV) with
percent (%) Ionization of imidazole lipid ·incorporated in eonvertible liposomes.
•Percent Ionization was calculated by Henderson-Hasselbal~h equation using
estimated average pKa values of imidazole lipids.

3.20 Phase separation of Jip(,lsome into lipid domains (DSC characterization). The
liposomes prepared with saturated lipids ofcarbon chain lengths diffe,ring by only two
carbon· atoms or Jess show ideal mixing of lipids (120) (121). The OSC thermogram ·of

lipoSome I (Fig. 3.15) show one broad melting

~ak

at pH 7.4 between 56 °C to 65 °C

indicating hom()genous mixing of the Ct6 and Cl8 chain lipids.

At pH 6;() the

fonnulatlon I shows the emergence of a second broad peak at 52° C suggesting the
fonnation of the domain rich in DSPCJipids (Tm = 55 °C) doped with the :C 16 chain

imidazole- lipids. The formation of 1he. DSPC domain- on the Jiposome is due to the
interaction of newly protonated imidazle Jipids and negatively charged PEGylated lipids

which squeezes out the DSPC lipids~ thi.l$ fonning a two phase system.
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3.15 DSC t.flerinogn!ni ofcontroLliposome IV and convertible Jiposome
fonnulation I

The DSC thermogram of the control liposome IV (Fig. 3.l5) show one melting ·peak
suggesting the homogenous mixing. of lipids at both pH 7.4 a~d 6;0 and therefore a one
•

phase system~
~-2l

Interaction of convertible liposomes with model liposomes mimic){ing

cell membrane. To evaluate whether the in~rease in the ·zeta potential values ii'J fact
translates into interaction with negatively charge cell

membrane~

we prepared model

liposorne ( 118)' (J 19) cai"tying t 5 mol % o f. negatjveJy charged lipids to mimic the

charge of the cell membrane (85) (8S). The convertible !iposom¢s. were mixed with equal

volume of equimolar ;model liposomes and their sizes were measured at .different pH
conditions.

Tbe increase in the average size of the model Hposome upon mbdng \\ ith the rlt
convertible- Jiposomes is consistent with the increase in th~ pKa ,-a lues ofthc inti,.U.ttlk
lipids and the corresponding increase in zeta potential of the res~('tivc: liposomcs (f'ia:.
3.16). Liposome formulation III shows approx. three tirn~s increase in a-\ cragc sitt'

values at pH 6.0 (:::: 2770 nm) compared to average sizes at pU 7.4.

Simit;nb

fonnulations I and ll show increase in average sizes 3.5- to 4- times >the \:alucs at plf7A .
The average sizes ofthe Jiposomes ofthe control liposomc on the mhc:r hand ~ht)\\cd no
significant change in the average sizes of the liposomal mixture at both the pt I
conditions.
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· 3.22 Doxotubiein loading in liposomes~ Doxorubicin has been conventionally Ioad'-'"d
in liperomes using an ammonium sulfate gradient wherein the concentration of

ammonium sulfate is higher in the Jiposome than· the extraliposomal medium. The pH
. inside .the liposome is maintained at 4M5 pH .units while the extraliposrnal pH is at pH 7A
The re_mote ·toading of DOX occurs when the

unprotonat~

DOX molecule diffuses from

the ~xtraliposo~alspace ·and gets charged atthe low pH environment inside the liposomc

and fot1llS a sulfate salt from the. sulfate

of the ammonrum sulfate ~olution {fig. J.J7).

The DOX-sulfate salt is then precipitated in the low pf I environment. The limitation with
this approach is.the t¢q~irement to form the liposomcs at low pH environments which is

a cha1Jengingtask for pH sensitive liposomes.

t!

fig. 3.17Loading ofDOX into liposomesby ammonium sulfate gradient
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' For our study, we·firstattempied a modificati<>n in·this.pt:ocedure where w¢ adjusted·tl}e
(NI-I4)2S04 solution to·pH7.0 instead·ofpH4-5 ~nd thenpr£>ceededwith lipid hydration,
extrusion, purification and remote loading of DQX. However, StiCh IllOdifkation resulted

in poor [)OX encapsulation(:::: 12 %) and poor DOX reteniion where only 40% ofthe
I

DOX remained inside the Iiposome after 50 h ofincubation at pH 7;4 at37 °C (Fig.. 3.18)
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Fig. 3:.18 OOX retention in convertible liposome fonntllation I at pH 7A prepared by
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J

I

1

To circumveri1 this problem we

prepar~ the IipoS()m~

mainta:inedatpH 7.4 (101). The manganese is known

itl mang:nese sulfate solution

to complex ~wiih OOX molecules-

j

..j
I

and therefore increase the retentiot:tofthedrug in liposome (101). The retention ofOOX
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with this method was at' around

64

% at pH 7.4 and . 56 % at pH 6.0 after 48 h of

inc~batiQn ar37-o C (Fig~ 3~19)
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Cytotoxicity of convertible Jiposumal·formulations ofDOX •. Bl6FIQ andHela

cells were treated with all the iiposomatfonnulations

(I~IV)'and

free. DOX. The free

DOX was studied as positi~e .control white .Ilposome IV was taken as a negative control..
AHthe fonnulations show·dose dependent c)itotoxitityin both ~ell l~es. The pHtunable
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liposomes show increased cytotoxicity as the pH is loweredfrom·7A to 6.0 at 10 Jlg/mL

DOX concentration both in complete media and serum·free media. In B16fl 0 cells, the
average tell viability values for formulations l, nand III were:::: 71 %, 75% and 50%

respectively at pH 7.4 while the averages values were :::: 59-%, 57 % and 41 %at pH 6.0
in serum free media at 10 Jlg/mLDOX.concentration after 3 hrs of incubation (Fig. 3.;2.0).
After 12 hr ofincubation the average cell viability values were:::: 57 o/o, 54 and 42% at
pH 7.4 and:::: 46 %, 43 % and 31 % at pH 6.0 respectively for .liposomes I, U, and Ill
(Fig. 3.21, 3•28). The control liposome IV did not show any significant difference

between the cell viabilities at pH 7.4 and 6.0 after 3 and 12 hrs of incubation (Fig. 3.20,

3.21 ).

Free DOX was the positive control and showed highest toxicities with cell

viability at :::: 25 % after 12 hours o( incubation at both pH values (Fig. 3~21, 3~28). The

c.Ytotoxities

we~ diminished

incubation although there was

for all fonnulations in complete media. After .3 hrs of

a clear trend in the decreasing cell

viabilities as the pH

decreased from 7.4 to 6.0, the values were not significantly different (Fig. 3.22).

However after 12 hours of incubation the cytotoxicity values for fonnulations I, 11, and
III became significantly different with liposome Ill showing highest cytotoxicity .at ::::
61% and:::: 52% cell viability at pH 7.4 arid 6.0 repectively (Fig.-3.23).
For He Ia cells, the cell viabilities w¢re :::: 67 %, 65 % and 53 % at pH 7.4 and ::::55%, 53
%and 43% at pH6.0 respectively for fonrtu1atioris I, II and lll after 3 hrs of incubation

in serum free media (Fig. 3~24). After 12 hrs of incubation with the convertible liposome
formulations I, II and III the cell·viability values were :::: 63 %, 58 % and 38 % at pH 7.4
and :::: 50 %, 46 % and 28 % at pH 6.0 (Fig. 3.25, 3.19). Free DOX showed highest
toxidty with :::: 22 % at both pH 7.4 and 6.0 (Fig. 3.25, 3.29). The observations for

Jl5

cytotoxicities in complete .media were similar as observed .in B16Ft0 cells where cell
viabilities did not show any significant difference at pH 7.4 and 6.0 for fonnutations 1? H
an£!

m (Fig• .3.26).

However cell viability difference at pH 7A and 6.0 did become

significant after 12 hours of incubation (Fig. 3~27) with. Jiposome III. showing highest

cytotoxicity at59 % and 51 %at pH 7A and 6.0 respectively.
For both the cell lines the increase. in toxicity was greater after 12 hours of in~ubation
compared to the 3 hr of incubation which indicates .the high uptake ofdrug by the ceHs at
longer times. Additionally, the difference-in the cytotoxicity (>f the c()ntr()l lip()some JV
remained insignificant at pH 7.4 and 6.0 at all DbX concentrations suggesting .its lack of
interaction with the negatively charged cell surface~
Furthennoret at both iilcubatic:m

times~

the cytotoxicity was greater for fonnulation III

which is consisteJ}t with the lip050me binding assay with model liposome, suggesting
more interaction of liposome with higher percentage of positive charges at low pH with
the negatively .charged cell surface and hence higher uptake and greater toxicity~
Also, the cytotoxicity ()felripty liposome I remained insignificant for all the experiments
indicating inherent insignificant cytotoxiciiy of the,imidazole lipids.
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Fig. 3.20 Cytotoxicity of free OOX, liposome formulations of DOX and empty liposome
(formulation I. without DOX) against B16-FI O murine melanoma cells in serum-free
medjum after three hours of incubation. Mean and SD of cell viability {%) are presented
(n = 4) (* p < 0.05, student t-test)
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Fig. 3.21 Cytotoxicity of free OOX, Jiposome formulations ofDOX and empty Iiposome
(formulation I without OOX) against BI6~Fl0 murine melanoma cells in serum·free
medium after twelve hours of incubation. Mean and SD of cell viability(%) are presented
(n = 4) (* p < 0.05, student t· test)
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Figure 3.22 Cytotoxicity of free OOX, liposome fonnulations of DOX and empty
Jiposome (fonnulation I without OOX) against B 16-FJO murine melanoma cells in
complete medium after three hours of incubation. Mean and SD of cell viability(%) are
presented (n = 4)
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(tonnulation I without OOX) against 816-FlO murine melanoma c.ells in complete
mediwn after twelve hours of incubation. Mean and SD of cell viability (%) are presented
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Fig. 3.24 Cytotoxicity of free OOX, liposome fonnulations of OOX and empty liposome
(fonnulation I without DOX) against Hela cells in serum-free medium after three hours
of incubation. Mean and SD of cell viability (%)are presented (n = 4) (* p < 0.05, student
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3.24

Cellular uptake of free DOX and li.,Osomal DOX. Based on the cytotoxicity

results of the previous section, the uptake of pH-convertible formulation II and control
liposome by B 16F I0 cells was characterized by flow cytometric analysis of the
fluorescence of the cargo drug doxorubicin. Free DOX was employed as the positive
control. A detachin solution (Genlantis, San Diego, CA) was used to detach cells as the
detachin is much milder than the trypsin for detachment and centrifugation of cells. The
time of incubation of the fonnations with the ceJis is critical as high time points result in
the high cell kill and which results in poor analysis ofthe OOX uptake by cells. On the
other hand a very short time may not result in sufficient formulation uptake by the cells.
After optimization, 4 hours of incubation was elected for the uptake stud.ies.
The flow cytometry data (Fig 3.30, 3.31) indicate that the change in mean fluorescent
intensity of cells incubated by controlliposome was not significant between pH 7.4 and
pH 6.0. In contrast, the average fluorescence values for liposome II show an increase of
57% at pH 6.0 compared to pH7.4. This clearly indicates higher OOX uptake by cells at
lowered pH owing to the increased interaction between the cells and the newly turned
cationic liposome n.
It is also interesting to note that the uptake of free DOX infact decreased at lowered pH,

which might be due to higher proportion of charged DOX molecules at low pH with
doxorubicin being a weakly basic drug. However, this small decrease did not trans1ate to
lower cytotoxicity of free OOX at pH 6.0
Our strategy to fonnulate doxorubicin in pH tunable liposomes insulates doxorubicin
from the low pH microenvironment and yet exploits the acidic microenvironment for the
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increase in the surface charge of the liposomes and subsequent greater interaction with
cancer cells.
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Cbapter4: .Summary and Conclusion

Lippsomal ~liug delivery system that can encapsulate and deliver anticancer agents ·was
developed in

our

studies.

Al_l ideal anticancer (jelivery system has primarily four

requirements; (l Jselectivity to c$cer (2) efficient delivery ofanticancer agent inside the
cancer cells (3) stability of the liposome formulation (4) high blood circulation half life~
To achieve.these goals. two strategies wer~ employed.
Firstly. a pH-sensitive Iiposome was envisaged by incorporating a

pH~sensitive

PEGy!ated lipid that can hydrolyze at low pH tumor environment. The hydrolysis at
mildly acidiC

tun1or cortdidons was envisioned to be exploited by placing a hydrazone

linker between the PEG head group and hydrocarbon chains of the PEGyJated lipid. The
shedding of PEG coating would expose positive charges and would result in greater
tumor interaction. The .synthesis of the hyd,rqzone-b~sed pH•sensitive lipid revealed that
the iipid hydrolyzes even at a neutral pH and was riot highly stable at physiological pH.
TberefQre, such approach would not be a good choice for developing a phannaceuticaiJy
viable drug delivery system.
To achieve the aforementioned goals; we changed the strategy .to desi~ing a pHconvertible liposome with more stable imidazole-based lipids. The design principal
works on the basis of acquisition .o f positive charges by protonation of the imidazole
moiety rather than hydrolysis. Such protonation strategy renders better formulation than
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· previously reponed acid-labile Jiposomes owing to its better· stability on shelf;

Additionally, the PEG coating on the surface of the convertible liposomes is also
clustered upon exposure to mildly acidic pH as seen. in tumor interstitium due to
electrostatic and vander waalmteraction between the protonated imidazole lipids and .the
negatively charged PEGyJated lipid.
We have used do:x:orubiciJ~ as the liposome cargo to study the cytotox.icity and cellular
uptake of these liposomes. DOX ·acts both as an anticancer age(lt ·encapsl.lhite4 in the
liposome and also as a fluorescent marker ofintracellular uptake of this. Jiposomal system

using flow .cytometty. The encapsulation and retention of our model drug doxorubicin
was enhanced·by using a previously reported manganese sulfate remote loading approach
(101).

Our cytotoxic studies indica,te the increase of cytotoxicity

at pH 6.0 in all · the

pH·

convertible liposomes compared to pH 7A in t\VO caric¢r cell lines (B 16 FlO and Hela).
Furthermore, the formulation (II) show significantly higher l!ptake in the B t6F 10 cells at

lower pH. The anticancer cytotoxicities of the pH-convertible lip()somes are better than
the control PEGylated Iiposomes which .werereported to·haveminiinum interaction with
the cancer cells and rely mostly on ·the slow release of drug from the fotinulation~ which

can be suboptimal to etlicieJtdy'ldlhhe cancer cells. The slow release·of doxoi'ubidn and

many other anticancer dnigs for a su~ined period can induce the: pr.eviously mentioned
'multi-drug resistance' and thereby further reducing the efficacy ofthe formulation.
Our studies ·s upports the approach of ¢xploiting the lower pH in tumotal inte~titium

by

carefuLchoice of lipids in the design ofliposomes thatinteract more strongly witlt cancer
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cells in response to lowered pH. Another potential advantage ofthi.S liposomal delivery

system would be its Jower cost because its lipid components are .either inexpensive or can
be conveniently synthesized.

It is interesting to note-that while increasing the pKa of the imidazole lipid does increase

the cytotoxic effect of the formulation, it also increases the interaction of these systems
with negatively charged model lipoS<>mes at the physiological pH. It remains to be

explored whether the increase in pKa of the imidazole Jipid in the liposomal fonnulation
would cause higher interactio[lwith components of blood in circu1ation,

Itis alsooimportant to notethatthe proposed liposome formulation will find:limitation in
patients with conditions ofmetabolic acidosis which rnay arise ·dUe tO dysfunction of liver
(lactic acidosis), kidney or lung (hypoventilation). The resultant decrease in blood pH
under such clinical situations may trigger premature display of positive charges by the
liposomes and subsequently their excessive Clearance from the blood~ by RES.
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